<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:02:55Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5090660" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5090660</identifier><datestamp>2016-11-25</datestamp><setSpec>emmolmed</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">EMBO Mol Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">EMBO Mol Med</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1757-4684</journal-id>
      <journal-id journal-id-type="publisher-id">EMMM</journal-id>
      <journal-id journal-id-type="hwp">embomm</journal-id>
      <journal-title-group>
        <journal-title>EMBO Molecular Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1757-4676</issn>
      <issn pub-type="epub">1757-4684</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5090660</article-id>
      <article-id pub-id-type="pmcid">PMC5090660</article-id>
      <article-id pub-id-type="pmc-uid">5090660</article-id>
      <article-id pub-id-type="pmid">27807076</article-id>
      <article-id pub-id-type="pmid">27807076</article-id>
      <article-id pub-id-type="doi">10.15252/emmm.201505815</article-id>
      <article-id pub-id-type="publisher-id">EMMM201505815</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A <italic><styled-content style="fixed-case">POGLUT</styled-content>1</italic> mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss</article-title>
        <alt-title alt-title-type="left-running-head">Emilia ServiÃ¡nâMorilla <italic>etÂ al</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib id="emmm201505815-cr-0001" contrib-type="author">
          <name>
            <surname>ServiÃ¡nâMorilla</surname>
            <given-names>Emilia</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505815-note-1001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0002" contrib-type="author">
          <name>
            <surname>Takeuchi</surname>
            <given-names>Hideyuki</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0003">
<sup>3</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-curr-0001">
<sup>15</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505815-note-1001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0003" contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Tom V</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0004">
<sup>4</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505815-note-1001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0004" contrib-type="author">
          <name>
            <surname>Clarimon</surname>
            <given-names>Jordi</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0005" contrib-type="author">
          <name>
            <surname>Mavillard</surname>
            <given-names>Fabiola</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0006" contrib-type="author">
          <name>
            <surname>AreaâGÃ³mez</surname>
            <given-names>Estela</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0007" contrib-type="author">
          <name>
            <surname>Rivas</surname>
            <given-names>Eloy</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0008">
<sup>8</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0008" contrib-type="author">
          <name>
            <surname>NietoâGonzÃ¡lez</surname>
            <given-names>Jose L</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0009" contrib-type="author">
          <name>
            <surname>Rivero</surname>
            <given-names>Maria C</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0010" contrib-type="author">
          <name>
            <surname>CabreraâSerrano</surname>
            <given-names>Macarena</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0011" contrib-type="author">
          <name>
            <surname>GÃ³mezâSÃ¡nchez</surname>
            <given-names>Leonardo</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0012" contrib-type="author">
          <name>
            <surname>MartÃ­nezâLÃ³pez</surname>
            <given-names>Jose A</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0013" contrib-type="author">
          <name>
            <surname>Estrada</surname>
            <given-names>Beatriz</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0009">
<sup>9</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0014" contrib-type="author">
          <name>
            <surname>MÃ¡rquez</surname>
            <given-names>Celedonio</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0015" contrib-type="author">
          <name>
            <surname>Morgado</surname>
            <given-names>Yolanda</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0010">
<sup>10</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0016" contrib-type="author">
          <name>
            <surname>SuÃ¡rezâCalvet</surname>
            <given-names>Xavier</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0011">
<sup>11</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0012">
<sup>12</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0017" contrib-type="author">
          <name>
            <surname>Pita</surname>
            <given-names>Guillermo</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0013">
<sup>13</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0018" contrib-type="author">
          <name>
            <surname>Bigot</surname>
            <given-names>Anne</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0014">
<sup>14</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0019" contrib-type="author">
          <name>
            <surname>Gallardo</surname>
            <given-names>Eduard</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0011">
<sup>11</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0012">
<sup>12</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0020" contrib-type="author">
          <name>
            <surname>FernÃ¡ndezâChacÃ³n</surname>
            <given-names>Rafael</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0021" contrib-type="author">
          <name>
            <surname>Hirano</surname>
            <given-names>Michio</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0022" contrib-type="author">
          <name>
            <surname>Haltiwanger</surname>
            <given-names>Robert S</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0003">
<sup>3</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-curr-0001">
<sup>15</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0023" contrib-type="author">
          <name>
            <surname>JafarâNejad</surname>
            <given-names>Hamed</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505815-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="emmm201505815-cr-0024" contrib-type="author" corresp="yes">
          <name>
            <surname>Paradas</surname>
            <given-names>Carmen</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6917-2236</contrib-id>
          <address>
            <email>cparadas@us.es</email>
          </address>
          <xref ref-type="aff" rid="emmm201505815-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505815-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="emmm201505815-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Neuromuscular Disorders Unit</named-content>
        <named-content content-type="organisation-division">Department of Neurology</named-content>
        <named-content content-type="organisation-division">Instituto de Biomedicina de Sevilla</named-content>
        <institution>Hospital U. Virgen del RocÃ­o/CSIC/Universidad de Sevilla</institution>
        <named-content content-type="city">Sevilla</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <institution>Centro de InvestigaciÃ³n BiomÃ©dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)</institution>
        <named-content content-type="city">Madrid</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Department of Biochemistry and Cell Biology</named-content>
        <institution>Stony Brook University</institution>
        <named-content content-type="city">Stony Brook</named-content>
        <named-content content-type="country-part">NY</named-content>
        <country country="US">USA</country>
      </aff>
      <aff id="emmm201505815-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of Molecular and Human Genetics</named-content>
        <institution>Baylor College of Medicine</institution>
        <named-content content-type="city">Houston</named-content>
        <named-content content-type="country-part">TX</named-content>
        <country country="US">USA</country>
      </aff>
      <aff id="emmm201505815-aff-0005">
        <label>
          <sup>5</sup>
        </label>
        <named-content content-type="organisation-division">Memory Unit</named-content>
        <named-content content-type="organisation-division">Department of Neurology and Sant Pau Biomedical Research Institute</named-content>
        <named-content content-type="organisation-division">Hospital de la Santa Creu i Sant Pau</named-content>
        <institution>Universitat AutÃ²noma de Barcelona</institution>
        <named-content content-type="city">Barcelona</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0006">
        <label>
          <sup>6</sup>
        </label>
        <named-content content-type="organisation-division">Department of Medical Physiology and Biophysics</named-content>
        <named-content content-type="organisation-division">Instituto de Biomedicina de Sevilla</named-content>
        <institution>Hospital U. Virgen del RocÃ­o/CSIC/Universidad de Sevilla</institution>
        <named-content content-type="city">Sevilla</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0007">
        <label>
          <sup>7</sup>
        </label>
        <named-content content-type="organisation-division">Department of Neurology</named-content>
        <institution>Columbia University Medical Center</institution>
        <named-content content-type="city">New York</named-content>
        <named-content content-type="country-part">NY</named-content>
        <country country="US">USA</country>
      </aff>
      <aff id="emmm201505815-aff-0008">
        <label>
          <sup>8</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pathology</named-content>
        <named-content content-type="organisation-division">Instituto de Biomedicina de Sevilla</named-content>
        <institution>Hospital U. Virgen del RocÃ­o/CSIC/Universidad de Sevilla</institution>
        <named-content content-type="city">Sevilla</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0009">
        <label>
          <sup>9</sup>
        </label>
        <named-content content-type="organisation-division">Centro Andaluz de BiologÃ­a del Desarrollo (CABD)</named-content>
        <institution>Universidad Pablo Olavide</institution>
        <named-content content-type="city">Sevilla</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0010">
        <label>
          <sup>10</sup>
        </label>
        <named-content content-type="organisation-division">Department of Neurology</named-content>
        <institution>Hospital U. Valme</institution>
        <named-content content-type="city">Sevilla</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0011">
        <label>
          <sup>11</sup>
        </label>
        <named-content content-type="organisation-division">Laboratori de Malalties Neuromusculars</named-content>
        <named-content content-type="organisation-division">Institut de Recerca de HSCSP</named-content>
        <institution>Universitat AutÃ²noma de Barcelona (UAB)</institution>
        <named-content content-type="city">Barcelona</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0012">
        <label>
          <sup>12</sup>
        </label>
        <institution>Centro de InvestigaciÃ³n BiomÃ©dica en Red sobre Enfermedades Raras (CIBERER)</institution>
        <named-content content-type="city">Barcelona</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0013">
        <label>
          <sup>13</sup>
        </label>
        <named-content content-type="organisation-division">Human Genotyping UnitâCeGen</named-content>
        <institution>Spanish National Cancer Research Centre</institution>
        <named-content content-type="city">Madrid</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="emmm201505815-aff-0014">
        <label>
          <sup>14</sup>
        </label>
        <named-content content-type="organisation-division">UPMC Univ Paris 06</named-content>
        <named-content content-type="organisation-division">INSERM UMRS974</named-content>
        <named-content content-type="organisation-division">CNRS FRE3617</named-content>
        <named-content content-type="organisation-division">Center for Research in Myology</named-content>
        <institution>Sorbonne UniversitÃ©s</institution>
        <named-content content-type="city">Paris</named-content>
        <country country="FR">France</country>
      </aff>
      <aff id="emmm201505815-curr-0001"><label><sup>15</sup></label>Present address: <named-content content-type="organisation-division">Complex Carbohydrate Research Center</named-content><institution>The University of Georgia</institution><named-content content-type="city">Athens</named-content><named-content content-type="country-part">GA</named-content><country country="US">USA</country></aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>Corresponding author. Tel: +34Â 955923045; Fax: +34Â 955013536; Eâmail: <email>cparadas@us.es</email></corresp>
        <fn fn-type="equal" id="emmm201505815-note-1001">
          <label>â </label>
          <p>These authors contributed equally to this work</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <volume>8</volume>
      <issue>11</issue>
      <issue-id pub-id-type="doi">10.1002/emmm.v8.11</issue-id>
      <fpage>1289</fpage>
      <lpage>1309</lpage>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>9</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>22</day>
          <month>8</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>9</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 EMBO <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2016 The Authors. Published under the terms of the CC BY 4.0 license</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EMMM-8-1289.pdf"/>
      <abstract id="emmm201505815-abs-0001">
        <title>Abstract</title>
        <p>Skeletal muscle regeneration by muscle satellite cells is a physiological mechanism activated upon muscle damage and regulated by Notch signaling. In a family with autosomal recessive limbâgirdle muscular dystrophy, we identified a missense mutation in <italic><styled-content style="fixed-case">POGLUT</styled-content>1</italic> (protein <italic>O</italic>âglucosyltransferase 1), an enzyme involved in Notch posttranslational modification and function. <italic>In vitro</italic> and <italic>inÂ vivo</italic> experiments demonstrated that the mutation reduces <italic>O</italic>âglucosyltransferase activity on Notch and impairs muscle development. Muscles from patients revealed decreased Notch signaling, dramatic reduction in satellite cell pool and a muscleâspecific Î±âdystroglycan hypoglycosylation not present in patients' fibroblasts. Primary myoblasts from patients showed slow proliferation, facilitated differentiation, and a decreased pool of quiescent <styled-content style="fixed-case">PAX</styled-content>7<sup>+</sup> cells. A robust rescue of the myogenesis was demonstrated by increasing Notch signaling. None of these alterations were found in muscles from secondary dystroglycanopathy patients. These data suggest that a key pathomechanism for this novel form of muscular dystrophy is Notchâdependent loss of satellite cells.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="emmm201505815-kwd-0001">muscular dystrophy</kwd>
        <kwd id="emmm201505815-kwd-0002">Notch</kwd>
        <kwd id="emmm201505815-kwd-0003"><italic>O</italic>âglycosylation</kwd>
        <kwd id="emmm201505815-kwd-0004"><styled-content style="fixed-case">POGLUT</styled-content>1</kwd>
        <kwd id="emmm201505815-kwd-0005">satelliteÂ cell</kwd>
      </kwd-group>
      <kwd-group kwd-group-type="subject-categories">
        <title>Subject Categories</title>
        <kwd>Development &amp; Differentiation</kwd>
        <kwd>Musculoskeletal System</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Instituto de Salud Carlos III</funding-source>
          <award-id>FIS PI10/02410</award-id>
          <award-id>PI13â01739</award-id>
          <award-id>BA12â00097</award-id>
          <award-id>FIS12/2291</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Muscular Dystrophy Association, USA</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>FederaciÃ³n EspaÃ±ola de Enfermedades Raras (FEDER)</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>El Centro de InvestigaciÃ³n BiomÃ©dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Andalusian Government</funding-source>
          <award-id>PIâ0017â2014</award-id>
          <award-id>P12âCTSâ2232</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>The Matsumae International Foundation</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>National Institute of General Medical Sciences</funding-source>
          <award-id>R01GM061126</award-id>
          <award-id>R01GM084135</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>National Institutes of Health</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>National Institute of Neurological Disorders and Stroke</funding-source>
          <award-id>U54 NS078059</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding-source>
          <award-id>R01 HD056103</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Agency for Management of University and Research Grants</funding-source>
          <award-id>2014SGR00235</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="9"/>
        <table-count count="0"/>
        <page-count count="21"/>
        <word-count count="14939"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>emmm201505815</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>November 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.7 mode:remove_FC converted:18.11.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="emmm201505815-cit-1001">
<source>EMBO Mol Med</source> (<year>2016</year>) <volume>8</volume>: <fpage>1289</fpage>â<lpage>1309</lpage>
<pub-id pub-id-type="pmid">27807076</pub-id></mixed-citation>
</p>
    </notes>
  </front>
  <body>
    <sec id="emmm201505815-sec-0001">
      <title>Introduction</title>
      <p>Cell surface glycans are diverse in structure and function and play critical roles in many biological processes including infection, cancer, and development (2009). Broadly speaking, glycans affect the function of proteins to which they are linked by modulating their structure and/or by serving as a direct recognition signal for other proteins (Varki &amp; Sharon, <xref rid="emmm201505815-bib-0071" ref-type="ref">2009</xref>). Glycans are involved in protein folding, stability, and trafficking and regulate the activity of important signaling pathways such as Notch, WNT, BMP, and Hedgehog (Christian, <xref rid="emmm201505815-bib-0013" ref-type="ref">2000</xref>; Yan &amp; Lin, <xref rid="emmm201505815-bib-0078" ref-type="ref">2009</xref>; JafarâNejad <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0033" ref-type="ref">2010</xref>; Takeuchi &amp; Haltiwanger, <xref rid="emmm201505815-bib-0069" ref-type="ref">2014</xref>). Not surprisingly, aberrant glycosylation leads to a variety of human diseases, the list of which is growing (Freeze <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0023" ref-type="ref">2014</xref>).</p>
      <p>Protein glycosylation can directly regulate signaling events. A clear example of this is the regulation of the evolutionarily conserved Notch signaling pathway, which is an intercellular communication mechanism widely used during animal development (Hori <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0031" ref-type="ref">2013</xref>). The extracellular domain of the Notch receptor is modified with <italic>O</italic>âfucose and <italic>O</italic>âglucose glycans (Moloney <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0047" ref-type="ref">2000</xref>). The structures of these glycans change in a tissueâspecific and developmentally regulated manner (Johnston <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0034" ref-type="ref">1997</xref>), and altering Notch glycosylation dramatically affects its activity (Stanley &amp; Okajima, <xref rid="emmm201505815-bib-0062" ref-type="ref">2010</xref>; Takeuchi &amp; Haltiwanger, <xref rid="emmm201505815-bib-0066" ref-type="ref">2010</xref>). One of the cell types whose regulation by Notch signaling has been intensely studied in recent years is the muscleâspecific adult stem cell called the satellite cell (SC) (Mourikis &amp; Tajbakhsh, <xref rid="emmm201505815-bib-0048" ref-type="ref">2014</xref>). SCs reside between the basal lamina and sarcolemma of myofibers (Mauro, <xref rid="emmm201505815-bib-0045" ref-type="ref">1961</xref>) and are the primary contributors to skeletal muscle growth and repair (Collins <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0016" ref-type="ref">2005</xref>). Despite continuous regeneration, pools of SC are maintained in healthy muscle. This is accomplished through asymmetric cell divisions of SC, which give rise both to selfârenewing SC and to committed myogenic progenitors that differentiate (Kuang <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0036" ref-type="ref">2007</xref>; Sacco <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0059" ref-type="ref">2008</xref>). In this process, the Notch pathway is key for maintaining quiescence in SC and for homing of SCâderived myoblasts (Bjornson <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0006" ref-type="ref">2012</xref>; Brohl <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0008" ref-type="ref">2012</xref>). A recent report indicates that mice in which Notch signaling is specifically blocked in SCs exhibit a decrease in the number of SCs and histological features of muscular dystrophy even upon normal daily activity (Lin <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0040" ref-type="ref">2013</xref>), suggesting that Notchâmediated maintenance of an active SC pool is essential for repairing muscle damage caused by regular activity and for maintaining healthy muscle. Muscular dystrophies are inherited disorders characterized by progressive weakness due to skeletal muscle degeneration, due to mutations in a growing list of responsible genes (Chandrasekharan &amp; Martin, <xref rid="emmm201505815-bib-0011" ref-type="ref">2010</xref>; Rahimov &amp; Kunkel, <xref rid="emmm201505815-bib-0053" ref-type="ref">2013</xref>). However, to date, no primary molecular defects in SC or Notch pathway components have been identified in human muscular dystrophies.</p>
      <p>Mutations in several genes disrupt various aspects of the dystrophinâassociated glycoprotein complex, which links the cytoskeleton to the extracellular matrix in muscle (Chandrasekharan &amp; Martin, <xref rid="emmm201505815-bib-0011" ref-type="ref">2010</xref>). A key component of this complex is dystroglycan (Ervasti <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0019" ref-type="ref">1990</xref>), a transmembrane protein essential for normal basement membrane development and muscle maintenance. Dystroglycan comprises a transmembrane Î²âsubunit nonâcovalently linked to an extracellular Î±âsubunit containing a mucinâlike domain, which is modified with numerous <italic>O</italic>âlinked glycans (Barresi &amp; Campbell, <xref rid="emmm201505815-bib-0003" ref-type="ref">2006</xref>). The Î²âsubunit is linked to the actin cytoskeleton, and the <italic>O</italic>âlinked glycans on the Î±âsubunit are critical for its binding capacity to extracellular matrix proteins such as laminin and agrin (Ervasti &amp; Campbell, <xref rid="emmm201505815-bib-0021" ref-type="ref">1993</xref>; Michele <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0046" ref-type="ref">2002</xref>). Mutations in dystroglycan itself result in the primary dystroglycanopathies (Henry &amp; Campbell, <xref rid="emmm201505815-bib-0029" ref-type="ref">1998</xref>; Cote <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0018" ref-type="ref">1999</xref>; Hara <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0027" ref-type="ref">2011</xref>; Willer <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0076" ref-type="ref">2014</xref>; Riemersma <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0056" ref-type="ref">2015</xref>; Kanagawa <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0035" ref-type="ref">2016</xref>). Secondary dystroglycanopathies are caused by interruption of Î±âdystroglycanâligand interactions due to mutations in a growing list of genes [currently eighteen (Bonnemann <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0007" ref-type="ref">2014</xref>)] encoding glycosyltransferases and accessory proteins responsible for Î±âdystroglycan's extensive posttranslational modifications (Muntoni <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0049" ref-type="ref">2011</xref>; Inamori <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0032" ref-type="ref">2012</xref>; YoshidaâMoriguchi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0080" ref-type="ref">2013</xref>). These include protein <italic>O</italic>âmannosyltransferase 1 (POMT1) and POMT2, which add <italic>O</italic>âlinked mannose to Î±âdystroglycan (Manya <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0044" ref-type="ref">2004</xref>; Willer <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0074" ref-type="ref">2004</xref>), and likeâacetylglucosaminyltransferase (LARGE), which is responsible for the addition of repeating xyloseâglucuronic acid units on the <italic>O</italic>âmannosyl glycans on Î±âdystroglycan (Inamori <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0032" ref-type="ref">2012</xref>). The dystroglycan gene (<italic>DAG1</italic>) is expressed in SCs (Cohn <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0015" ref-type="ref">2002</xref>), but glycosylated Î±âdystroglycan is not required by myogenic cells during proliferation (Awano <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0002" ref-type="ref">2015</xref>), a notion supported by the observation that trace amounts of glycosylated Î±âdystroglycan are found in C2C12 and human primary myoblasts during proliferation. Cultures of freshly isolated muscle fibers suggest that glycosylation of Î±âdystroglycan is needed for proliferation of SCs <italic>inÂ vivo</italic>, but it is not necessary when SCs are removed from their niche (Ross <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0057" ref-type="ref">2012</xref>). The transition to larger glycans occurs rapidly after differentiation is induced, and a direct correlation exists between LARGEâdependent extension of <italic>O</italic>âglycans on Î±âdystroglycan and its function as an extracellular matrix receptor (Goddeeris <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0025" ref-type="ref">2013</xref>). Despite extensive studies regarding the genetics of dystroglycanopathies, the responsible gene is still unknown in a significant number of patients; thus, mutations in additional genes will likely be implicated in this group of diseases.</p>
      <p>Here, we report a homozygous missense mutation (D233E) in the protein <italic>O</italic>âglucosyltransferase 1 gene, <italic>POGLUT1</italic>, in four siblings with autosomal recessive limbâgirdle muscular dystrophy. POGLUT1 is the sole enzyme that directly adds <italic>O</italic>âglucose to a distinct serine residue of epidermal growth factorâlike (EGF) repeats containing a CX<underline underline-style="single">S</underline>X(P/A)C consensus sequence (Rana <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0055" ref-type="ref">2011</xref>), many of which are found in Notch extracellular domains (FernandezâValdivia <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0022" ref-type="ref">2011</xref>; Rana <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0055" ref-type="ref">2011</xref>). The D233E mutation dramatically reduces the <italic>O</italic>âglucosyltransferase activity of POGLUT1, leading to impaired Notch signaling and a dramatic decrease in the number of SCs in adult muscles. Transgenic experiments in <italic>Drosophila</italic> indicate that D233E impairs the ability of human POGLUT1 to rescue the muscle phenotype caused by the loss of fly Poglut1 activity. Patient muscles show Î±âdystroglycan hypoglycosylation and decreased binding to laminin, but normal binding to agrin and normal basement membrane structure. Moreover, unlike other dystroglycanopathies, patient fibroblasts exhibit normal Î±âdystroglycan glycosylation and laminin binding. Together, our findings indicate that exhaustion of the SC pool plays a primary role in this novel form of muscular dystrophy.</p>
    </sec>
    <sec id="emmm201505815-sec-0002">
      <title>Results</title>
      <sec id="emmm201505815-sec-0003">
        <title>Clinical and radiological findings</title>
        <p>A consanguineous family from southern Spain comprises 17 individuals spanning three generations (FigÂ <xref rid="emmm201505815-fig-0001" ref-type="fig">1</xref>A). Four out of five siblings from generation II presented a phenotype consistent with a limbâgirdle muscular dystrophy. Specifically, the patients exhibited muscle weakness predominantly in the proximal lower limbs, with onset during the third decade. The disease course was progressive, leading to scapular winging and wheelchair confinement. For more extended clinical data regarding this family, see the <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Information</xref>, <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1</xref>, and AppendixÂ Tables <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">S1</xref> and <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">S2</xref>. Serum creatine kinase level was normal in three patients and mildly elevated in one (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S1</xref>). Muscle biopsies from all four affected siblings revealed histological features ranging from very mild myopathic changes to classic dystrophic pathology (FigÂ <xref rid="emmm201505815-fig-0001" ref-type="fig">1</xref>A). Proteins typically affected in myopathies displayed normal expression in muscle, except for a reduction in Î±âdystroglycan (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S2</xref>). Muscle magnetic resonance imaging (MRI) of the legs revealed a striking pattern of muscle involvement (FigÂ <xref rid="emmm201505815-fig-0001" ref-type="fig">1</xref>C), with early fatty replacement of internal regions of thigh muscles that spared external areas. This âfrom insideâtoâoutsideâ mode of fatty degeneration progressed over the years and did not match the distribution patterns typically associated with other forms of muscular dystrophies (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Information</xref> and AppendixÂ Figs <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">S3</xref> and <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">S4</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <title>
<italic>POGLUT1</italic> missense mutation in a family with a limbâgirdle muscular dystrophy</title>
            <p>
<list list-type="alpha-upper" id="emmm201505815-list-0002"><list-item><p>The family pedigree, where circles denote female members, squares male members, solid symbols affected members, and white symbols asymptomatic members with normal physical exam; the dots indicate heterozygous carriers, and double line denotes a consanguineous marriage. The pictures show scapular winging, which is a consistent clinical sign in affected individuals.</p></list-item><list-item><p>Hematoxylin and eosin staining (H&amp;E) of skeletal muscle from patient II.1 shows histological features of moderateâtoâsevere dystrophic pattern. Scale bar, 50Â Î¼m.</p></list-item><list-item><p>T1âweighted MRI axial images at thigh and calf levels show that the fatty degeneration is more prominent in thigh muscles, equally affecting posterior and anterior compartments, with relative sparing of the rectus femoris, sartorius, and gracilis muscles until late stages (4, 10, and 11, respectively). Strikingly, the fatty tissue is located in the internal parts of almost all the affected muscles in thigh (1, 2, 3, 5â9), while the external regions are spared. At calf level, only the gastrocnemius medialis muscle (12) shows this pattern, while the soleus (13) is diffusely involved. Patient II.2 (PII.2) shows lateâstage thigh muscles with an unusual involvement of the tibialis posterior muscle (14) in the lower leg.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="EMMM-8-1289-g002"/>
        </fig>
      </sec>
      <sec id="emmm201505815-sec-0004">
        <title>Expression and functional modification of Î±âdystroglycan inÂ patients</title>
        <p>Given the key role played by aberrant Î±âdystroglycan glycosylation and function in a subset of muscular dystrophies and because of the observed decrease in Î±âdystroglycan levels in patient muscles, we examined the glycosylation status and ligandâbinding ability of Î±âdystroglycan in our patients. Immunofluorescence staining of frozen cross sections from skeletal muscle biopsy with an antibody against glycosylated Î±âdystroglycan [IIH6 (Ervasti &amp; Campbell, <xref rid="emmm201505815-bib-0020" ref-type="ref">1991</xref>)] revealed a variable reduction in the glycosylated form of Î±âdystroglycan at the sarcolemma in patients, while antibodies against Î±âdystroglycan core protein, Î²âdystroglycan, and laminin Î±2 showed normal staining (FigÂ <xref rid="emmm201505815-fig-0002" ref-type="fig">2</xref>A and <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S5A</xref>). In agreement with this observation, Western blots showed a reduction in Î±âdystroglycan glycosylation in patient muscle, accompanied by a mild decrease in the molecular weight of glycosylated Î±âdystroglycan compared with controls. To examine whether decreased Î±âdystroglycan glycosylation affected binding to ligands, we performed a ligand overlay assay. As shown in FigÂ <xref rid="emmm201505815-fig-0002" ref-type="fig">2</xref>B, the lamininâbinding activity was diminished in muscle. However, the agrinâbinding activity to the patients' muscle extracts showed no difference compared with controls (FigÂ <xref rid="emmm201505815-fig-0002" ref-type="fig">2</xref>B). Moreover, in skin fibroblasts from patients, the level of both functional Î±âdystroglycan glycosylation, examined by Western blot and flow cytometry (Stevens <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0064" ref-type="ref">2013b</xref>), and its ability to bind laminin (FigÂ <xref rid="emmm201505815-fig-0002" ref-type="fig">2</xref>B and <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S5B</xref>) were normal, unlike known secondary dystroglycanopathies, which usually result in decreased functional Î±âdystroglycan glycosylation in both muscle and the skin fibroblasts (Willer <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0075" ref-type="ref">2012</xref>; Carss <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0009" ref-type="ref">2013</xref>; Stevens <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0063" ref-type="ref">2013a</xref>). Finally, although basement membrane defects are commonly observed in dystroglycanopathies (Yamamoto <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0077" ref-type="ref">1997</xref>; Goddeeris <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0025" ref-type="ref">2013</xref>), transmission electron microscopy showed normal muscle ultrastructure in patients, with no alterations in basement membrane compaction (FigÂ <xref rid="emmm201505815-fig-0002" ref-type="fig">2</xref>C and <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S5C</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <title>A muscleâspecific decrease in Î±âdystroglycan glycosylation and laminin binding upon <italic>POGLUT1</italic> mutation</title>
            <p>
<list list-type="alpha-upper" id="emmm201505815-list-0003"><list-item><p>Muscle sections show variable labeling using an antibody against glycosylated Î±âdystroglycan (Î±DGâIIH6), whereas labeling using antibodies against Î±âdystroglycan core protein (Î±DGâCore), Î²âdystroglycan (Î²DG), and lamininâÎ±2 is similar to control (scale bar, 100Â Î¼m).</p></list-item><list-item><p>Western blots and ligand overlay (O/L) of wheat germ agglutininâenriched muscle and fibroblasts lysates from PII.2, PII.5, the healthy sibling (HII.3), and healthy controls (Ctr, Ctr1, and Ctr2) (muscle: 250Â Î¼g protein/lane, fibroblasts: 800Â Î¼g/lane). In muscle, expression of Î±DGâIIH6 is reduced, but the Î±DGâCore shows similar expression as controls, with a slight reduction in molecular weight; laminin overlay assay detected some binding activity but was diminished compared with controls, whereas agrinâbinding activity showed no difference with controls. In fibroblasts, both Î±DGâIIH6 and Î±DGâCore expression and lamininâbinding activity were normal, suggesting that unlike other muscular dystrophies, Î±âdystroglycan glycosylation defect is muscle specific in <italic>POGLUT1</italic> patients.</p></list-item><list-item><p>No ultrastructural alterations are observed in muscle by electron microscopy (6â7 fields were captured from PII.1, PII.3, and PII.5). Note normal basement membrane compaction (arrowheads). Original magnification: Ã26,700.</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="EMMM-8-1289-g003"/>
        </fig>
        <p>These observations suggest that although a partial decrease in Î±âdystroglycan functional glycosylation is detected in muscle from our patients, decreased Î±âdystroglycan glycosylation is unlikely to be caused by the same pathomechanism seen in secondary dystroglycanopathies and that a mutation in a gene other than the enzymes directly involved in Î±âdystroglycan glycosylation might underlie this disease.</p>
      </sec>
      <sec id="emmm201505815-sec-0005">
        <title>D233E mutation in <italic>POGLUT1</italic>
</title>
        <p>Homozygosity mapping in DNA samples through genomewide genotyping arrays containing ~ one million single nucleotide polymorphisms (SNPs) revealed a unique (&gt;Â 500Â kb) region of homozygosity identical by descent in the four affected siblings and absent in their healthy sister (FigÂ <xref rid="emmm201505815-fig-0003" ref-type="fig">3</xref>A). This 14.6 megabase region on chromosome 3q13.13âq21.2, defined by SNP markers rs13081374 and rs2333038, included 112 proteinâcoding genes (FigÂ <xref rid="emmm201505815-fig-0003" ref-type="fig">3</xref>B and C). No structural genomic variations were shared by affected family members, thus excluding gross gene dosage change as a cause of disease. We next performed whole exome sequencing of patients II.4, II.5, and their healthy sister II.3 and found a c.699TÂ &gt;Â G transversion within <italic>POGLUT1</italic> (FigÂ <xref rid="emmm201505815-fig-0003" ref-type="fig">3</xref>D). The polymorphism produces an asparticâtoâglutamic substitution at amino acid residue 233 (p.D233E), which passed all possible filtering, segregated with the disease, and consequently was suspected to be the causal genetic alteration.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <title>
<italic>POGLUT1</italic> D233E mutation in patients</title>
            <p>
<list list-type="alpha-upper" id="emmm201505815-list-0004"><list-item><p>Genomewide mapping through highâdensity genotyping. The structural genomic variation and extended regions of homozygosity (loss of heterozygosity [LOH]) over the entire genome is shown for individuals II.1 to II.5. The homozygosity segment shared by the four affected siblings in chromosome 3 is indicated with an arrow.</p></list-item><list-item><p>This region is represented in more detail, where extended regions of homozygous genotypes in contiguous biallelic polymorphisms are highlighted with a green background.</p></list-item><list-item><p>The 14.6 megabase region of homozygosity that is shared by all affected siblings is highlighted by vertical red lines in (B), and genes within this genomic region are shown. Note that <italic>POGLUT1</italic> gene is underlined.</p></list-item><list-item><p>Chromatograms reveal a homozygous TâtoâG substitution (black boxes and arrowheads) in the four affected family members, while a heterozygous G/T in the healthy sibling.</p></list-item><list-item><p>Schematic structure of the human POGLUT1 protein, which contains a signal peptide (SP), a CAP10 domain, and a LysâAspâGluâLeu (KDEL)âlike endoplasmic reticulum retention signal. D233E is located in the CAP10 domain (arrow), close to the predicted ERD catalytic motif (asterisk). Alignment of amino acids flanking the mutated aspartic acid from POGLUT1 orthologs indicates evolutionary conservation of D233 in vertebrates (open arrowhead). Black boxes denote similarity of amino acid residues.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="EMMM-8-1289-g004"/>
        </fig>
        <p>Significantly, <italic>POGLUT1</italic> is located within the 3q13.13âq21.2 region of homozygosity in the affected siblings (FigÂ <xref rid="emmm201505815-fig-0003" ref-type="fig">3</xref>C). The mutation was not found in the Exome Aggregation Consortium (ExAC) database (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>) [accessed in February 2015], thus discarding this genetic variant in 60,698 individuals (36,673 Europeans). In addition, the D233E mutation was further excluded in 919 DNA samples from 57 populations worldwide (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S3</xref>).</p>
        <p>The mutated aspartic acid residue is located in the capsuleâassociated protein (CAP)10 domain, 14 amino acids apart from the putative ERD catalytic motif, and is highly conserved across vertebrate species (FigÂ <xref rid="emmm201505815-fig-0003" ref-type="fig">3</xref>E).</p>
      </sec>
      <sec id="emmm201505815-sec-0006">
        <title>Expression of POGLUT1<sup>D233E</sup> in patients</title>
        <p>We assessed the effect of the D233E mutation on the expression of POGLUT1 in samples from patients. In skeletal muscle, Western blot showed normal protein expression and qRTâPCR assays showed no difference in the <italic>POGLUT1</italic> mRNA level compared with controls. In skin biopsyâderived fibroblasts, immunostaining revealed a colocalization of POGLUT1<sup>D233E</sup> with the endoplasmic reticulum, displaying the same pattern as the wildâtype POGLUT1 in human control fibroblasts (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S6</xref>). These data indicate that the D233E mutation does not affect the expression level or subcellular localization of POGLUT1.</p>
      </sec>
      <sec id="emmm201505815-sec-0007">
        <title>Biochemical assays of D233E mutation in <italic>POGLUT1</italic>
</title>
        <p>We next analyzed the effect of the D233E mutation on the <italic>O</italic>âglucosyltransferase activity of POGLUT1 by biochemical assays. Wildâtype and D233E mutant forms of humanâPOGLUT1 were transiently expressed in HEK293T cells and purified from the culture media (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S7A</xref>). We examined the enzymatic activity of purified proteins toward a known substrate: bacterially expressed epidermal growth factorâlike (EGF) repeat from human coagulation factor IX (hFIX). POGLUT1<sup>D233E</sup> mutant showed significantly lower activity than wild type (FigÂ <xref rid="emmm201505815-fig-0004" ref-type="fig">4</xref>A). <italic>O</italic>âglucosyltransferase activity was dependent on the concentrations of EGF repeat and UDPâglucose (acceptor and donor substrate, respectively). POGLUT1<sup>D233E</sup> also showed lower activity than wild type toward five different single EGF repeats from mouse Notch1 (FigÂ <xref rid="emmm201505815-fig-0004" ref-type="fig">4</xref>B), suggesting that the mutation affects <italic>O</italic>âglucosylation of all EGF repeats containing the <italic>O</italic>âglucose consensus sequence (CX<underline underline-style="single">S</underline>X(P/A)C) (Rana <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0055" ref-type="ref">2011</xref>). Prior work has shown that POGLUT1 also has protein <italic>O</italic>âxylosyltransferase activity toward certain EGF repeats with a diserine motif within the <italic>O</italic>âglucose consensus sequence (e.g. EGF16 of mouse Notch2) (Takeuchi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0067" ref-type="ref">2011</xref>). POGLUT1<sup>D233E</sup> mutant also showed lower <italic>O</italic>âxylosyltransferase activity than wild type (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S7B</xref>). To examine whether POGLUT1<sup>D233E</sup> retains any enzymatic activity, we performed overnight incubation and then analyzed the products by reverseâphase HPLC and mass spectrometry. Both wild type and the D233E mutant added a single glucose or xylose to the hFIXâEGF repeat (FigÂ <xref rid="emmm201505815-fig-0004" ref-type="fig">4</xref>C) or EGF16 from mouse Notch2 (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S7C</xref>), indicating that POGLUT1<sup>D233E</sup> has residual enzymatic activity.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <title>POGLUT1<sup>D233E</sup> has lower enzymatic activity than wild type</title>
            <p>
<list list-type="alpha-upper" id="emmm201505815-list-0005"><list-item><p>Protein <italic>O</italic>âglucosyltransferase activity of wildâtype (WT) or D233E mutant POGLUT1 protein toward human factor IX EGF repeat (hFIXâEGF). Wild type shows higher <italic>O</italic>âglucosyltransferase activity than D233E, and this activity is dependent on the concentration of the acceptor substrate hFIXâEGF repeat (left) and on the concentration of donor substrate UDPâglucose (UDPâGlc) (right). Values indicate meanÂ Â±Â SEM from three independent assays.</p></list-item><list-item><p>
<italic>O</italic>âGlucosyltransferase activity toward five different single EGF repeats from mouse Notch1. Wildâtype POGLUT1 shows higher activity toward all EGF repeats tested than POGLUT1<sup>D233E</sup>. The <italic>y</italic>âaxis shows the normalized activity relative to wildâtype POGLUT1. EGF repeats were at 10Â Î¼M. Values indicate meanÂ Â±Â SEM from three independent assays.</p></list-item><list-item><p>Elution profiles of the POGLUT1 reaction products on reverseâphase HPLC. hFIXâEGF repeat was incubated with wildâtype or D233E mutant POGLUT1 and donor substrate, UDPâGlc or UDPâxylose (UDPâXyl), at 37Â°C overnight. Values on top of the peaks indicate the measured masses. Addition of Glc (162Â Da) or xylose (132Â Da) to hFIXâEGF (5696.2Â Da) by wildâtype POGLUT1 caused a shift to an earlier retention time (left). Similarly, the products exhibited a similar shift after incubation with POGLUT1<sup>D233E</sup> (right). These results indicate that POGLUT1<sup>D233E</sup> can add a single glucose or xylose to hFIXâEGF repeats and thus has residual enzymatic activity.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="EMMM-8-1289-g005"/>
        </fig>
      </sec>
      <sec id="emmm201505815-sec-0008">
        <title>Analysis of Notch signaling pathway and satellite cells in D233E patients</title>
        <p>Mutations in the <italic>Drosophila</italic> gene <italic>rumi</italic>, which encodes the flyâPOGLUT1, result in a temperatureâsensitive loss of Notch signaling (Acar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0001" ref-type="ref">2008</xref>). Moreover, <italic>Poglut1</italic> knockdown in mouse myoblast C2C12 cells results in a significant decrease in <italic>O</italic>âglucosyltransferase activity and impaired Notch signaling (FernandezâValdivia <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0022" ref-type="ref">2011</xref>). Accordingly, we examined the expression of activated Notch and the levels of Notch downstream targets in patient muscles. Decreases in Notch1âintracellular domain expression and in <italic>HES1</italic> mRNA levels in skeletal muscle were detected compared with controls, which support that D233E affects Notch activity (FigÂ <xref rid="emmm201505815-fig-0005" ref-type="fig">5</xref>A and B). Notch signaling is critical in normal postnatal myogenesis by regulating SC maintenance (Bjornson <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0006" ref-type="ref">2012</xref>), at least in part by directly inducing the expression of <italic>Pax7</italic>, which encodes a transcription factor critical for the maintenance of adult SC (Olguin &amp; Olwin, <xref rid="emmm201505815-bib-0052" ref-type="ref">2004</xref>). Indeed, treating proliferating C2C12 cells with the Î³âsecretase inhibitor DAPT, which blocks Notch signaling, significantly reduced the mRNA levels of <italic>Pax7</italic> (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S8</xref>). Likewise, we found a decrease in <italic>PAX7</italic> mRNA and fewer PAX7<sup>+</sup> cells in the muscle of patients compared with controls (FigÂ <xref rid="emmm201505815-fig-0005" ref-type="fig">5</xref>C and D). Together, these observations suggest that the D233E mutation affects the selfârenewal of SC by reducing Notch signaling, likely due to defective <italic>O</italic>âglucosylation.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <title>Muscles from D233E patients show decreased Notch signaling and pool of satellite cells</title>
            <p>
<list list-type="simple" id="emmm201505815-list-0006"><list-item><label>A</label><p>Western blot of muscle homogenates shows reduced expression of Notch1 intracellular domain (NICD) in patients.</p></list-item><list-item><label>B, C</label><p>qRTâPCR on RNA extracted from skeletal muscle shows that expression of <italic>HES1</italic> (B) and <italic>PAX7</italic> (C) was significantly lower in D233E patients compared with healthy controls. MeanÂ Â±Â SEM; Student's <italic>t</italic>âtest (B) and MannâWhitney <italic>U</italic>âtest (C).</p></list-item><list-item><label>D</label><p>PAX7<sup>+</sup> cells in skeletal muscle sections, demonstrating that satellite cells are less abundant in D233E patients than in controls (<italic>nÂ </italic>=<italic>Â </italic>3 muscles with 10â15 fields analyzed per muscle). MeanÂ Â±Â SEM; MannâWhitney <italic>U</italic>âtest; scale bar, 50Â Î¼m.</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-13" xlink:href="EMMM-8-1289-g006"/>
        </fig>
        <p>We analyzed the same parameters in patients suffering from other muscular dystrophies, and also in patients suffering from a secondary dystroglycanopathy, whose muscle biopsies showed mildâtoâmoderate dystrophic changes, similar to our patients. Both groups show significantly higher levels of activated Notch and higher numbers of PAX<sup>+</sup> cells compared with D233E patients (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S9AâH</xref>). These data support the notion that the observed decrease in Notch1 signaling and PAX7<sup>+</sup> cells in D233E patients is not secondary to Î±âdystroglycan hypoglycosylation.</p>
      </sec>
      <sec id="emmm201505815-sec-0009">
        <title>
<italic>In vivo</italic> functional study of POGLUT1<sup>D233E</sup>
</title>
        <p>To investigate the <italic>inÂ vivo</italic> effects of the D233E mutation on POGLUT1 function in muscle progenitors, we performed crossâspecies rescue experiments in the context of adult myogenesis in <italic>Drosophila</italic>, a process regulated by Notch signaling (Gildor <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0024" ref-type="ref">2012</xref>). In these experiments, we used the <italic>rumi</italic>
<sup><italic>79</italic></sup> allele, which harbors a missense mutation that abolishes flyâPOGLUT1 enzymatic activity but does not affect its expression (Acar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0001" ref-type="ref">2008</xref>). When raised at 18Â°C, <italic>rumi</italic>
<sup><italic>79/79</italic></sup> animals exhibited normal indirect flight muscle development and a large number of myoblasts expressing the transcription factor Twist, which is a downstream target of Notch activation (FigÂ <xref rid="emmm201505815-fig-0006" ref-type="fig">6</xref>AâBâ³). However, when <italic>rumi</italic>
<sup><italic>79/79</italic></sup> animals were raised at 25 and 30Â°C during the early pupal stage, when these muscles form, muscle development was dramatically impaired and the number of Twist<sup>+</sup> myoblasts was severely decreased (FigÂ <xref rid="emmm201505815-fig-0006" ref-type="fig">6</xref>CâDâ³). The severe temperatureâsensitive defects observed in indirect flightÂ muscle development in <italic>rumi</italic>
<sup><italic>79/79</italic></sup> animals indicate that adult myoblast development in flies depends on the enzymatic activity of flyâPOGLUT1. Overexpression of wildâtype humanâPOGLUT1âFLAG in muscle progenitors rescued the muscle phenotypes of <italic>rumi</italic>
<sup><italic>79/79</italic></sup> animals (FigÂ <xref rid="emmm201505815-fig-0006" ref-type="fig">6</xref>E). However, the overexpression of humanâPOGLUT1<sup>D233E</sup>âFLAG only showed a weak and variable rescue of the muscle morphology and myoblast numbers in <italic>rumi</italic>
<sup><italic>79/79</italic></sup> animals (FigÂ <xref rid="emmm201505815-fig-0006" ref-type="fig">6</xref>FâH), indicating that this mutation significantly decreases the ability of POGLUT1 to promote muscle development and Notch signaling in myoblasts. It is interesting to note that flyâPOGLUT1 harbors a glutamic acid (E) at position 252, which is equivalent to D233 in humanâPOGLUT1 (FigÂ <xref rid="emmm201505815-fig-0003" ref-type="fig">3</xref>E). Given the robust protein <italic>O</italic>âglucosyltransferase activity of the flyâPOGLUT1 and because 35% of the amino acids in the CAP10 enzymatic domains of human and fly POGLUT1 are divergent (Acar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0001" ref-type="ref">2008</xref>), other amino acid differences between these two proteins are likely to be the reason why the fly protein is fully functional despite harboring the equivalent of the D233E mutation.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0006" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <title>Loss of Rumi results in temperatureâsensitive <italic>Drosophila</italic> muscle defects and is only weakly rescued by POGLUT1<sup>D233E</sup> expression</title>
            <p>
<list list-type="simple" id="emmm201505815-list-0007"><list-item><label>AâAâ³</label><p>Staining of <italic>Drosophila</italic> indirect flight muscles at 25% pupal development with 22C10 antibody (myotube marker) and antiâTwist antibody (myoblast marker) indicates that in wildâtype animals, indirect flight muscles are formed from six myotubes, and a large number of Twist<sup>+</sup> myoblasts are present.</p></list-item><list-item><label>BâBâ³</label><p>
<italic>rumi</italic>
<sup><italic>79/79</italic></sup> mutants raised at 18Â°C show no obvious defects in myoblast number or myotube morphology.</p></list-item><list-item><label>CâDâ³</label><p>
<italic>rumi</italic>
<sup><italic>79/79</italic></sup> mutants exhibit decreased number of myoblasts at 25â30Â°C and either an incomplete set of short myotubes when raised at 25Â°C or aberrant morphology of myotubes when raised at 30Â°C.</p></list-item><list-item><label>EâEâ³</label><p>
<italic>rumi</italic>
<sup><italic>79/79</italic></sup> animals overexpressing FLAGâtagged POGLUT1<sup>WT</sup> in the muscle compartment using <italic>Mef2âGAL4</italic> and raised at 25Â°C during the pupal stage show a rescue of the <italic>rumi</italic>
<sup><italic>79/79</italic></sup> muscle phenotype.</p></list-item><list-item><label>FâGâ³</label><p>Overexpression of FLAGâtagged POGLUT1<sup>D233E</sup> only partially rescues the <italic>rumi</italic>
<sup><italic>79/79</italic></sup> muscle phenotype, with some variation in the myotube length and the number of restored Twist<sup>+</sup> cells (compare G and F). Note that the number of Twist<sup>+</sup> cells restored by POGLUT1<sup>D233E</sup> is much smaller than that restored by POGLUT1<sup>WT</sup>.</p></list-item><list-item><label>H</label><p>Quantification of myotube lengths in <italic>rumi</italic>
<sup><italic>79/79</italic></sup> mutants with or without POGLUT1 expression indicates a weak rescue of the phenotypes by POGLUT1<sup>D233E</sup> compared with POGLUT1<sup>WT</sup>. The differences in myotube lengths are statistically significant. For <italic>rumi</italic>
<sup><italic>79/79</italic></sup> rescue (left bar), 5 animals were used and a total of 23 myotubes were measured; for D233E rescue, 11 animals and 54 myotubes; for WT rescue, 5 animals and 22 myotubes. Mean Â± SD is shown; oneâway ANOVA with Bonferroni's multiple comparisons test.</p></list-item></list>Data information: Scale bar in (Aâ²) is 50Â Î¼m and applies to (AâGâ³).<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-15" xlink:href="EMMM-8-1289-g007"/>
        </fig>
      </sec>
      <sec id="emmm201505815-sec-0010">
        <title>
<italic>Ex vivo</italic> analysis of D233E primary myoblasts</title>
        <p>Previous studies have shown that the Notch signaling pathway not only plays an important role in maintaining satellite cell quiescence, but also enhances myoblast proliferation and inhibits myogenic differentiation (Conboy &amp; Rando, <xref rid="emmm201505815-bib-0017" ref-type="ref">2002</xref>; Bjornson <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0006" ref-type="ref">2012</xref>; Mourikis &amp; Tajbakhsh, <xref rid="emmm201505815-bib-0048" ref-type="ref">2014</xref>).</p>
        <p>In order to directly test our hypothesis that the decrease in the POGLUT1 enzymatic activity caused by the D233E mutation disrupts muscle cell function, we explored myogenesis in D233E primary myoblasts from patient muscle biopsies compared with healthy and disease controls (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S10</xref>). We quantified the percentage of selfârenewing, proliferating, and differentiating cells based on PAX7 and MyoD expression. Quantitative analysis in myoblasts cultured in a growth medium revealed that the percentage of PAX7<sup>+</sup>MyoD<sup>+</sup> (proliferating) cells in D233E cells was significantly lower than those in healthy and disease controls (FigÂ <xref rid="emmm201505815-fig-0007" ref-type="fig">7</xref>AâC). The percentage of PAX7<sup>+</sup> cells and PAX7<sup>+</sup>MyoD<sup>â</sup> (selfârenewing) cells was significantly decreased in D233E samples (FigÂ <xref rid="emmm201505815-fig-0007" ref-type="fig">7</xref>D and E), whereas the percentage of PAX7<sup>â</sup>MyoD<sup>+</sup> (differentiating) cells was increased (FigÂ <xref rid="emmm201505815-fig-0007" ref-type="fig">7</xref>F). When myoblasts reached confluence, they were cultured in a differentiation medium. We observed more efficient myoblast fusion into the multinucleated myotubes and higher levels of myogenin expression in D233E cultures compared with controls (FigÂ <xref rid="emmm201505815-fig-0007" ref-type="fig">7</xref>GâI). The slow proliferation and facilitated differentiation of mutant myogenic cells are in agreement with decreased Notch activity in the muscle of D223E patients.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0007" orientation="portrait" position="float">
          <label>Figure 7</label>
          <caption>
            <title>D233E primary myoblasts exhibit decreased proliferation and increased differentiation</title>
            <p>
<list list-type="simple" id="emmm201505815-list-0008"><list-item><label>AâF</label><p>Proliferation assays examined proliferating (PAX7<sup>+</sup> MyoD<sup>+</sup>, arrows), selfârenewing (PAX7<sup>+</sup> MyoD<sup>â</sup>, open arrows), and differentiating (PAX7<sup>â</sup> MyoD<sup>+</sup>, arrowheads) cells from D233E patients (<italic>nÂ </italic>=<italic>Â </italic>2), healthy controls (<italic>nÂ </italic>=<italic>Â </italic>3), and disease controls (<italic>nÂ </italic>=<italic>Â </italic>3) at 1, 4, and 8Â days growing in proliferation medium. PanelÂ (A) shows representative images from day 8. The number of patient myoblasts is lower than that of controls at all three time points, indicating a slower proliferation rate in patient myoblasts (B), and accordingly, the percentage of proliferating cells (C) is smaller in the patient. (D) The percentage of selfârenewing cells is small in patient's culture, reflecting a poor capacity for maintaining the pool of quiescent SCs. In addition, the percentage of PAX7<sup>+</sup> cells (E) is smaller in patient's culture, similar to what was found in adult D233E muscle (shown in FigÂ <xref rid="emmm201505815-fig-0005" ref-type="fig">5</xref>D). (F) The percentage of differentiating cells is higher in the patient. We examined proliferation capturing 7â12 randomly fields per day and condition (meanÂ Â±Â SEM is shown; KruskalâWallis with Dunn's multiple comparisons test; scale bar, 50Â Î¼m).</p></list-item><list-item><label>GâI</label><p>When myoblasts started to be confluent, the proliferation medium was replaced with differentiation medium, and the myoblasts started to fuse yielding myotubes, which were analyzed after 4Â days of differentiation. (H) The fusion index, which measures the percentage of nuclei in myotubes with respect to the total number of nuclei in myogenic cells, was higher in D233E cultures than in controls. (I) Besides, myogenin showed increased expression in D233E myoblast cultures compared with controls. The data support that differentiation process is facilitated in patient's muscle. Data were collected from 3 to 10 randomly chosen areas per condition (meanÂ Â±Â SEM is shown; KruskalâWallis with Dunn's multiple comparisons test (H) and oneâway ANOVA with Bonferroni's multiple comparisons test (I); scale bar, 50Â Î¼m).</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-17" xlink:href="EMMM-8-1289-g008"/>
        </fig>
        <p>Due to the scarcity of cells obtained from fresh patient's muscles in culture (likely because of the severe defect in proliferation of D233E myoblasts), we performed immortalization of the primary myoblasts (Mamchaoui <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0043" ref-type="ref">2011</xref>), and conversion of skin fibroblasts from patients to myogenic cells by transduction of inducible MyoD (Choi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0012" ref-type="ref">1990</xref>). Thus, we generated two different continuous myogenic cell lines with the D233E mutation, which showed similar phenotypic features, although PAX7 expression started after 1â3Â days in culture in the myogenic cell line (AppendixÂ Figs <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">S11</xref> and <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">S12</xref>). To examine whether increasing Notch pathway activity can rescue the alterations of the myogenic process observed in D233E immortalized myoblasts during differentiation in culture, we used lentivirus to overexpress NICD1 in these cells and observed a solid reversion of the proliferation defects (FigÂ <xref rid="emmm201505815-fig-0008" ref-type="fig">8</xref>A and B, <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S13A and B</xref>). However, we did not observe rescue of the amount of PAX7<sup>+</sup> cells (FigÂ <xref rid="emmm201505815-fig-0008" ref-type="fig">8</xref>C). It has been described that the effect of Notch on the expression of PAX7 in myogenic cell lines such as C2C12 is not as potent as in primary myoblasts (Sun <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0065" ref-type="ref">2008</xref>). This probably hindered the modification of PAX7 expression during the rescue experiment. In addition, NICD1 overexpression robustly rescued the facilitated differentiation shown by D233E myoblasts in culture (FigÂ <xref rid="emmm201505815-fig-0008" ref-type="fig">8</xref>D, AppendixÂ Figs <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">S13C</xref> and <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">S14</xref>), and this rescue was demonstrated by the fusion index (FigÂ <xref rid="emmm201505815-fig-0008" ref-type="fig">8</xref>E) and expression of myogenin (FigÂ <xref rid="emmm201505815-fig-0008" ref-type="fig">8</xref>F). These results support the pathogenic role of decreased Notch signaling in this novel muscular dystrophy.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0008" orientation="portrait" position="float">
          <label>Figure 8</label>
          <caption>
            <title>Rescue experiments on immortalized primary myoblasts by lentiviral infection</title>
            <p>
<list list-type="simple" id="emmm201505815-list-0009"><list-item><label>AâC</label><p>We overexpressed NICD in immortalized primary myoblasts to rescue the features displayed by immortalized D233E myoblasts. (B) We analyzed the proliferation at 1, 3, and 5Â days, and proliferation rate in patientâLVâNICDâGFP reached the level observed in controlâLVâGFP, which were higher than in patientâLVâGFP. (C) However, the percentage of PAX7<sup>+</sup> cells in patientâLVâNICDâGFP showed the same reduced value as in patientâLVâGFP, which were significantly lower than in controlâLVâGFP. The majority of control myoblasts were proliferating cells (PAX7<sup>+</sup> MyoD<sup>+</sup>, arrows), with no quiescent cells and few differentiating cells (PAX7<sup>â</sup> MyoD<sup>+</sup>, arrowheads) detected. Data were collected from <italic>nÂ </italic>=<italic>Â </italic>2 independent assays (5â8 images per condition). MeanÂ Â±Â SEM is shown; oneâway ANOVA with Tukey multiple comparisons test (B) and KruskalâWallis with Dunn's multiple comparisons test (C); scale bar, 50Â Î¼m.</p></list-item><list-item><label>DâF</label><p>As previously described in patient's primary myoblasts, patientâLVâGFP myoblasts showed a striking facilitated differentiation compared with controlâLVâGFP myoblasts. This phenotype fully disappeared in patientâLVâGFPâNICD myoblasts, as quantification of the fusion index (E), and myogenin expression (F) demonstrated. The data support a pathogenic role for Notch inhibition on the altered differentiation in our patients. Data were collected from <italic>nÂ </italic>=<italic>Â </italic>3 independent assays (13â17 images per condition). MeanÂ Â±Â SEM is shown; KruskalâWallis with Dunn's multiple comparisons test; scale bar, 50Â Î¼m.</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-19" xlink:href="EMMM-8-1289-g009"/>
        </fig>
      </sec>
      <sec id="emmm201505815-sec-0011">
        <title>Role of Notch on Î±âdystroglycan glycosylation</title>
        <p>As shown in FigÂ <xref rid="emmm201505815-fig-0002" ref-type="fig">2</xref>, our patients exhibit a muscleâspecific reduction in Î±âdystroglycan glycosylation. The only known protein domain to which POGLUT1 can add carbohydrates is a properly folded EGF repeat containing the CX<underline underline-style="single">S</underline>X(P/A)C consensus sequence (Takeuchi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0068" ref-type="ref">2012</xref>). Since Î±âdystroglycan contains no EGF repeats nor CXSX(P/A)C sites, it is unlikely to be a direct target of glycosylation by POGLUT1. A recent study has shown that in transgenic mice and C2C12 myoblasts, Î±âdystroglycan glycosylation is a progressive process that initiates rapidly after myoblasts are induced to differentiate, and exhibits a regular and gradual transition to a larger glycoforms to reach the normal level after 5Â days of differentiation (Goddeeris <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0025" ref-type="ref">2013</xref>). In order to evaluate this progressive pattern of Î±âdystroglycan glycosylation, primary immortalized myoblasts were differentiated. After 5Â days with differentiation medium, D233E myoblasts showed a lower level and irregular progression profile of Î±âdystroglycan glysosylation compared with controls, which reproduced the same pattern previously demonstrated in C2C12 cells (Goddeeris <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0025" ref-type="ref">2013</xref>) (FigÂ <xref rid="emmm201505815-fig-0009" ref-type="fig">9</xref>A). These observations are compatible with abnormal differentiation dynamics in patient myoblasts. Given the wellâestablished role of Notch signaling in muscle differentiation, we hypothesized that decreased Notch signaling in D233E patients' myoblasts might contribute to altered Î±âdystroglycan glycosylation. We first attempted to test this hypothesis by asking whether NICD overexpression can restore Î±âdystroglycan glycosylation in patient myoblasts. However, given the strong inhibition of differentiation upon NICD overexpression, we were unable to do this, as in both cases (rescued and not rescued patient's myoblasts) Î±âdystroglycan glycosylation was immature (FigÂ <xref rid="emmm201505815-fig-0009" ref-type="fig">9</xref>B). Next, we examined whether inhibition of Notch signaling leads to altered pattern of Î±âdystroglycan glycosylation during differentiation. To this end, we differentiated C2C12 cells with medium containing DAPT or LY3039478 to decrease Notch signaling. The cells showed a reduced expression of glycosylated Î±âdystroglycan at all differentiation days (FigÂ <xref rid="emmm201505815-fig-0009" ref-type="fig">9</xref>CâF). These results support the notion that Î±âdystroglycan hypoglycosylation is the consequence of Notch inactivation, produced by the reduced activity of POGLUT1 in the case of our patients.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505815-fig-0009" orientation="portrait" position="float">
          <label>Figure 9</label>
          <caption>
            <title>Effects of decreased Notch signaling on Î±âdystroglycan glycosylation during differentiation</title>
            <p>
<list list-type="simple" id="emmm201505815-list-0010"><list-item><label>A</label><p>Immortalized primary myoblasts from a healthy control showed a progressive pattern of Î±âdystroglycan glycosylation during 5Â days of differentiation (D0âD5), as has been previously described by Goddeeris <italic>etÂ al</italic> (<xref rid="emmm201505815-bib-0025" ref-type="ref">2013</xref>). Immortalized primary myoblasts from patients displayed an irregular pattern of glycosylation, with a final level of glycosylated Î±âdystroglycan that was lower than control.</p></list-item><list-item><label>B</label><p>Î±âdystroglycan glycosylation of infected immortalized myoblasts from patientâLVâNICDâGFP at differentiation day 5 (D5) showed a striking reduction, in line with the strong inhibition of myotubes formation and differentiation induced by NICD overexpression. Î±âdystroglycan in myoblasts from patientâLVâGFP showed a reduction in glycosylation compared with controlâLVâGFP at D5, similar to the results obtained in the adult muscle from patients (FigÂ <xref rid="emmm201505815-fig-0002" ref-type="fig">2</xref>).</p></list-item><list-item><label>C, D</label><p>C2C12 myogenic cells showed a reduced level of glycosylated Î±âdystroglycan when the Notch signaling inhibitor DAPT or LY3039478 was added to the differentiation medium. This indicates that reducing Notch signaling can affect Î±âdystroglycan glycosylation in wildâtype C2C12 myoblasts cells, which do not harbor any known mutations in Î±âdystroglycan glycosyltransferases or Poglut1.</p></list-item><list-item><label>E, F</label><p>qRTâPCR experiments show that upon DAPT or LY3039478 treatment, a remarkable decrease in <italic>Hes1</italic> mRNA is induced in C2C12 cells during differentiation. Three replicates per condition were analyzed; mean Â± SEM is shown.</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-21" xlink:href="EMMM-8-1289-g010"/>
        </fig>
      </sec>
    </sec>
    <sec id="emmm201505815-sec-0012">
      <title>Discussion</title>
      <p>Transgenic mice in which the panâNotch inhibitor dnMAML1 is specifically expressed in muscle SC were recently shown to display reduced PAX7 expression in SC cells and muscular dystrophic features even without experimentally induced injury (Lin <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0040" ref-type="ref">2013</xref>). This study highlighted the role of Notch signaling and SCs in repairing the muscle damage caused by regular activity in a mammal, suggesting that a primary defect in SC maintenance caused by decreased Notch signaling can in principle result in muscular dystrophy. However, direct evidence from human patients was lacking to support this notion. Here, we describe a family in which a recessive D233E mutation severely impairs the enzymatic activity of POGLUT1, leading to a marked reduction in Notch activation in adult muscle, a decreased pool of PAX7<sup>+</sup> SCs, and a partial defect of Î±âdystroglycan functional glycosylation. The findings in this family sharply contrast with those in other forms of ageâmatched limbâgirdle muscular dystrophy, including secondary dystroglycanopathies, which show normal levels of <italic>HES1</italic> and <italic>PAX7</italic> transcripts in adult muscles (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S9</xref>).</p>
      <p>Although patients' muscles display reduced glycosylation of Î±âdystroglycan, several findings are inconsistent with a secondary dystroglycanopathy. First, the patients do not have elevated creatine kinase and muscle biopsies do not show many degenerative fibers compared with that observed in secondary dystroglycanopathies (Cirak <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0014" ref-type="ref">2013</xref>). Second, the D233E muscles exhibit reduced Î±âdystroglycan lamininâbinding activity but show normal agrinâbinding and compact basement membrane ultrastructure. Although it is known that LARGEâdependent glycosylation of Î±âdystroglycan is required for the binding of both laminin and agrin, the precise glycan structures recognized by these ligands have not been determined. Agrin, but not laminin, showed normal binding to Î±âdystroglycan in patients' muscle, suggesting that these ligands may recognize slightly different glycan structures on Î±âdystroglycan. Third, Î±âdystroglycan expression and laminin binding are normal in D233E skin fibroblasts. In contrast, other forms of dystroglycanopathy usually exhibit markedly diminished or no binding for both laminin and agrin in muscle, together with defective muscular basement membrane compaction (Michele <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0046" ref-type="ref">2002</xref>; Hara <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0027" ref-type="ref">2011</xref>; Willer <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0075" ref-type="ref">2012</xref>; Goddeeris <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0025" ref-type="ref">2013</xref>). Moreover, the published results show that secondary dystroglycanopathies caused by mutations in known genes result in reduced functional Î±âdystroglycan glycosylation in patient fibroblasts, and in the majority of patients, the level of Î±âdystroglycan glycosylation is comparable in fibroblasts and skeletal muscle from the same patient (Carss <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0009" ref-type="ref">2013</xref>). These observations further support the notion that, although decreased laminin binding in muscle is likely to contribute to pathology in our patients, Î±âdystroglycan hypoglycosylation might not be the disease mechanism caused by the D233E mutation, or at least the primary mechanism.</p>
      <p>Strikingly, our data suggest that the D233E mutation causes defects in SC proliferation and differentiation. The amount number of SCs in our patients is significantly reduced even in very early stages when the muscle is barely affected, compared with healthy and disease controls. Alterations in SC proliferation have been described in the Large<sup>myd</sup> mouse dystroglycanopathy model and are thought to contribute to myodegeneration in these animals (Ross <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0057" ref-type="ref">2012</xref>). In this model, SCs are significantly increased at early stages and have reduced proliferation when cultured on freshly isolated single fibers; however, proliferation is restored in culture when SCs are removed from the fibers, indicating that rather than intrinsic defects in myoblasts, compositional changes in the extracellular matrix due to hypoglycosylated Î±âdystroglycan are responsible for the proliferative alteration. In contrast, myoblasts from our patients displayed reduced proliferation and selfârenewal capacity in culture when removed from their fiber niche, supporting an intrinsic defect in D233E myoblasts independent of Î±âdystroglycan hypoglycosylation. Moreover, it has been recently demonstrated in dystroglycanopathy mice models that functional glycosylation of Î±âdystroglycan does not play a significant role in myogenic cell proliferation and differentiation (Awano <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0002" ref-type="ref">2015</xref>). Our results indicate that the D233E mutation results in deficient Notch signaling in patient muscle and an impairment in the regulation of myoblast differentiation and that expression of NICD rescues this phenotype. Our results strongly suggest that impaired myogenesis mediated by decreased Notch signaling is a causal mechanism of muscular dystrophy in our patients (FigÂ <xref rid="emmm201505815-fig-0008" ref-type="fig">8</xref>). Although we expected that the reduction in PAX7<sup>+</sup> cells in our patients would be a direct effect of Notch inhibition, the lack of rescue of PAX7<sup>+</sup> cells by NICD overexpression suggests something more complicated. The effect of Notch on PAX7 expression has been reported to be weaker in myogenic cell lines than in primary myoblasts, and this could be affecting the rescue of PAX7<sup>+</sup> cells in our system (Sun <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0065" ref-type="ref">2008</xref>). Nevertheless, our data consistently demonstrated a decreased number of PAX7<sup>+</sup> cells in D233E patients, compared with healthy and disease controls, including secondary dystroglycanopathies. This result together with a previous report showing that the blockade of Notch signaling in muscle SCs of a mouse model causes muscular dystrophy and impairs muscle regeneration (Lin <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0040" ref-type="ref">2013</xref>) supports our hypothesis that impaired regulation of muscle SC homeostasis plays a pathogenic role in this new muscle dystrophy. Recent findings demonstrate that the overexpression of Jagged1, a major ligand of the Notch signaling pathway, ameliorates the dystrophic phenotype in the golden retriever muscular dystrophic dogs, which is an excellent model to the human dystrophynopathy, indicating that the Notch pathway can be considered a new therapeutic target in muscular dystrophies (Vieira <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0073" ref-type="ref">2015</xref>).</p>
      <p>POGLUT1 specifically adds <italic>O</italic>âglucose or <italic>O</italic>âxylose to properly folded EGF repeats containing the CX<underline underline-style="single">S</underline>X(P/A)C consensus sequence (Rana <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0055" ref-type="ref">2011</xref>; Takeuchi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0067" ref-type="ref">2011</xref>, <xref rid="emmm201505815-bib-0068" ref-type="ref">2012</xref>) and is among the glycosyltransferases that directly add sugar molecules to an amino acid, not to other sugars. Therefore, since Î±âdystroglycan lacks EGF repeats and the CX<underline underline-style="single">S</underline>X(P/A)C consensus sequence, POGLUT1 is highly unlikely to directly add carbohydrates to Î±âdystroglycan core protein or to extend the carbohydrate chains added to Î±âdystroglycan by other glycosyltransferases. This is supported by our observation that glycosylation of Î±âdystroglycan from D233E skin fibroblasts is normal. These data strongly argue that POGLUT1 does not participate in the biosynthesis of the <italic>O</italic>âmannose glycans on Î±âdystroglycan. Therefore, unlike POMT1/2 and LARGE which add carbohydrates to Î±âdystroglycan to regulate muscle maintenance, POGLUT1 most likely glycosylates other target proteins to maintain muscle integrity. This notion is supported by our fly experiments: Loss of POGLUT1 enzymatic activity in <italic>Drosophila</italic> also causes a severe decrease in the number of Twist<sup>+</sup> myoblasts and muscle development, which can be fully rescued by wildâtype humanâPOGLUT1 but only weakly so by POGLUT1<sup>D233E</sup>. However, <italic>Drosophila</italic> dystroglycanopathy models, including null alleles of <italic>dystroglycan</italic>, do not have defects in myoblast migration and myofiber formation (Nakamura <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0050" ref-type="ref">2010</xref>), indicating that the muscle phenotypes observed in <italic>rumi</italic> flies are not caused by alterations in dystroglycan.</p>
      <p>Fourteen <italic>Drosophila</italic> proteins and about 50 mammalian proteins have EGF repeats with a CX<underline underline-style="single">S</underline>X(P/A)C consensus sequence and are therefore predicted to be modified by POGLUT1 (JafarâNejad <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0033" ref-type="ref">2010</xref>; Rana <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0055" ref-type="ref">2011</xref>; Haltom <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0026" ref-type="ref">2014</xref>). This consensus motif is highly predictive of enzymatic modification, as mass spectrometric analyses have demonstrated that most if not all EGF repeats with a CX<underline underline-style="single">S</underline>X(P/A)C motif examined so far are <italic>O</italic>âglucosylated (Hase <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0028" ref-type="ref">1988</xref>; Acar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0001" ref-type="ref">2008</xref>; FernandezâValdivia <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0022" ref-type="ref">2011</xref>; Rana <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0055" ref-type="ref">2011</xref>; Lee <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0037" ref-type="ref">2013</xref>; Haltom <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0026" ref-type="ref">2014</xref>; Ramkumar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0054" ref-type="ref">2015</xref>; Thakurdas <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0070" ref-type="ref">2016</xref>). Agrin, which is implicated in muscle disease, is predicted to have a single POGLUT1 target site. However, we did not observe any defects in agrin's level, molecular size, or its capacity to bind Î±âdystroglycan in our patient muscles, strongly suggesting that impaired agrin glycosylation cannot explain the muscular dystrophy in our patients. Indeed, the addition of <italic>O</italic>âglucose to a target protein by POGLUT1 does not necessarily indicate functional importance. For example, even though <italic>Drosophila</italic> Crumbs is <italic>O</italic>âglucosylated, homozygosity for a knockâin allele of the <italic>Drosophila crumbs</italic> in which all seven Crumbs <italic>O</italic>âglucosylation sites are mutated does not recapitulate <italic>crumbs</italic> lossâofâfunction phenotypes during fly development and generates viable and fertile adults (Haltom <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0026" ref-type="ref">2014</xref>). Among the confirmed POGLUT1 biochemical targets, <italic>Drosophila</italic> Notch, mouse Notch1, mouse CRUMBS2, and <italic>Drosophila</italic> Eyes shut are shown to be functionally regulated by POGLUT1âmediated glycosylation (Acar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0001" ref-type="ref">2008</xref>; FernandezâValdivia <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0022" ref-type="ref">2011</xref>; Leonardi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0038" ref-type="ref">2011</xref>; Haltom <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0026" ref-type="ref">2014</xref>; Ramkumar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0054" ref-type="ref">2015</xref>). Moreover, there is evidence suggesting that mouse JAG1 might also be a biologically relevant target of POGLUT1, although further experiments are required to prove this (Thakurdas <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0070" ref-type="ref">2016</xref>). Based on the severe decrease in Notch signaling and Notch1 cleavage in ourÂ patients' muscle, the dramatic decrease in the ability of POGLUT1<sup>D233E</sup> to glycosylate Notch EGF repeats, and previous observations on the role of POGLUT1 and Notch receptor <italic>O</italic>âglucosylation in Notch signaling (Acar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0001" ref-type="ref">2008</xref>; FernandezâValdivia <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0022" ref-type="ref">2011</xref>; Leonardi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0038" ref-type="ref">2011</xref>; Ma <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0041" ref-type="ref">2011</xref>; Rana <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0055" ref-type="ref">2011</xref>), we propose that the Notch receptors are the key target of POGLUT1 in the muscle. However, we cannot exclude that other POGLUT1 targets might also contribute to the phenotypes observed in our patients.</p>
      <p>If POGLUT1 affects a glycosylation pathway unrelated to the <italic>O</italic>âmannose glycans, it raises the question of why <italic>O</italic>âmannose glycosylation on Î±âdystroglycan is impaired in D233E muscle. Our data strongly favor an indirect mechanism for Î±âdystroglycan hypoglycosylation, likely due to altered myogenesis caused by decreased Notch signaling resulting from the D233E mutation. Indeed, a recent report showed that Î±âdystroglycan glycosylation is at a low level during the first stages of muscle regeneration even in wildâtype mice and is increased as myogenesis proceeds (Goddeeris <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0025" ref-type="ref">2013</xref>). The authors proposed that coordination between myogenic differentiation and increased expression of the glycosyltransferase LARGE results in bulkier Î±âdystroglycan molecules with more extensive LARGEâmediated glycosylation and thereby a more robust ligandâbinding capacity during muscle repair (Goddeeris <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0025" ref-type="ref">2013</xref>). Accordingly, Î±âdystroglycan hypoglycosylation in our patients can be a consequence of altered SC homeostasis and differentiation, which would impede muscle repair and potentially result in immature LARGEâmediated glycosylation (FigÂ <xref rid="emmm201505815-fig-0009" ref-type="fig">9</xref>). Previous data show that an adequate balance of Notch activation is needed during myogenesis (Kuang <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0036" ref-type="ref">2007</xref>; Sacco <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0059" ref-type="ref">2008</xref>), and our results support an additional critical role of Notch signaling in the process of Î±âdystroglycan glycosylation during muscle differentiation. Nonetheless, the muscleâspecific Î±âdystroglycan hypoglycosylation could contribute to muscle dystrophy in our patients.</p>
      <p>An autosomalâdominant dermatosis has recently been associated with heterozygous mutations in <italic>POFUT1</italic> (protein <italic>O</italic>âfucosyltransferase 1, which adds <italic>O</italic>âfucose to Notch), and <italic>POGLUT1</italic> (Li <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0039" ref-type="ref">2013</xref>; Basmanav <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0004" ref-type="ref">2014</xref>). <italic>Drosophila</italic> Pofut1 has a chaperoneâlike function on the Notch protein independent of its <italic>O</italic>âfucosyltransferase activity (Okajima <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0051" ref-type="ref">2005</xref>). Therefore, since patients homozygous for D233E have deficient enzymatic activity but normal POGLUT1 expression and no skin abnormalities, this dermatosis could be due to a defect in a nonâenzymatic function of POGLUT1. However, genetic background differences could also exist that make these patients more sensitive to a 50% reduction in POGLUT1 enzymatic activity.</p>
      <p>In conclusion, we identified the human <italic>POGLUT1</italic> D233E mutation that impairs Notch posttranslational modification and maintenance of muscle stem cells and leads to muscular degeneration and Î±âdystroglycan hypoglycosylation. Our findings demonstrate that D233E mutation in POGLUT1 causes autosomal recessive limbâgirdle muscular dystrophy and implicate a primary defect in muscle progenitor cells as a novel pathomechanism for muscular dystrophy. Our patients display an adultâonset pure muscular phenotype, in contrast to the lethal, multisystemic phenotypes observed in animals with complete loss of POGLUT1 (Acar <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0001" ref-type="ref">2008</xref>; FernandezâValdivia <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0022" ref-type="ref">2011</xref>). Thus, the residual <italic>O</italic>âglucosyltransferase activity in our patients is sufficient for other aspects of human development and tissue homeostasis, indicating that myoblasts are particularly sensitive to decreased POGLUT1 activity.</p>
    </sec>
    <sec id="emmm201505815-sec-0013">
      <title>Materials and Methods</title>
      <sec id="emmm201505815-sec-0014">
        <title>Skeletal muscle histology and ultrastructural study</title>
        <p>Open muscle biopsies were obtained from biceps brachii or quadriceps of the four patients and the healthy sibling in generation II of the family. The muscle was rapidly frozen in liquid nitrogenâchilled isopentane and 7âÎ¼mâthick cryostat sections were stained for standard histological and histochemical techniques including hematoxylin and eosin, Gomori trichrome, nicotinamide adenine dinucleotide dehydrogenase (NADH), and ATPase pH 9.4. Stained sections were evaluated with an Olympus BX41 (Tokyo, Japan) equipped with a ColorView IIIu camera (Olympus).</p>
        <p>A piece of muscle from each biopsy was fixed in glutaraldehyde, embedded in Embed 812 resin, and processed for electron microscopy by standard methods (Malfatti <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0042" ref-type="ref">2013</xref>). Ultrathin sections were viewed with Philips CM10 electron microscope (Eindhoven, Netherlands) equipped with Gatan 1k CCD camera.</p>
      </sec>
      <sec id="emmm201505815-sec-0015">
        <title>Antibodies</title>
        <p>The list of the primary antibodies used in this study is provided in <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S7</xref>. The antiâÎ±âdystroglycan core protein (a kind donation from S. KrÃ¶ger) sheep polyclonal antibody was raised against a synthetic peptide corresponding to the carboxyâterminal 20 amino acids of chick Î±âdystroglycan (Herrmann <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0030" ref-type="ref">2000</xref>).</p>
      </sec>
      <sec id="emmm201505815-sec-0016">
        <title>Immunohistochemical studies</title>
        <p>Unfixed frozen muscle sections were incubated with primary antibodies overnight at 4Â°C, and then with the appropriate secondary antibodies for 30Â min.</p>
        <p>Cultured myoblasts were permeabilized in 0.2% Triton Xâ100 for 10Â min and incubated in 1% BSA/PBS for 45Â min; frozen sections were incubated in 5% normal goat serum/PBS for 45Â min. Primary antibodies were used as described in <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S7</xref> and incubated for 12Â h at 4Â°C. After washing, samples were incubated with the appropriate secondary antibodies for 1Â h.</p>
        <p>PAX7 immunohistochemistry was carried out according to an antigen retrieval protocol, modified from Song <italic>etÂ al</italic> (<xref rid="emmm201505815-bib-0060" ref-type="ref">2012</xref>). Briefly, samples were fixed with 4% paraformaldehyde, pHÂ =Â 7.4 (PFA) for 15Â min. Sections were then immersed in citrate buffer (pH 6) for 30Â min at 80Â°C and washed with PBS. Afterward, tissue samples were blocked with nonâfat milk at 2% in PBS for 30Â min and washed with PBS. Next, tissue sample were incubated with primary antibody for 2Â days and secondary antibody for 2Â h in blocking solution (5% BSA, 0.5% Triton Xâ100 in PBS). Î±DGâCORE immunohistochemistry required incubation with both biotinylated secondary antibody for 30Â min and streptavidin conjugated to Cy3 for 15Â min in PBS. Finally, the nuclei were stained for 20Â min with Toâproâ3âIodide (Topro) at 1:1,000 in PBS and the slides were coverslipped with fluorescence mounting medium (Dako). The images were acquired on a Zeiss LSM 710 confocal laser scanning microscope. Maximal projections of Zâstacked images were obtained and analyzed with ImageJ software.</p>
      </sec>
      <sec id="emmm201505815-sec-0017">
        <title>Glycoprotein enrichment and Western blot analysis</title>
        <p>Frozen muscle samples and fresh skin fibroblasts were homogenized in RIPA buffer (20Â mM TrisâHCl pH 7.4, 150Â mM NaCl, 1Â mM EDTA, 1% IGEPAL, 0.1% SDS) containing protease inhibitor mixture. Western blots of glycoproteins were enriched with wheatâgerm agglutinin (WGA) agarose (SigmaâAldrich) as described previously (Michele <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0046" ref-type="ref">2002</xref>). Equivalent amounts of protein lysates nonâincubated or incubated with WGA agarose beads were resolved on 7â10% SDSâPAGE gels and transferred to PDVF membranes (Millipore). Immunoreactivity was detected with secondary antibodies conjugated to horseradish peroxidase (Jackson Immuno Research) and developed with SuperSignal West Femto (Thermo Scientific) using an ImageQuant LAS 4000 MiniGold System (GE Healthcare).</p>
      </sec>
      <sec id="emmm201505815-sec-0018">
        <title>Ligand overlay assay</title>
        <p>Ligand overlay assays in muscle and skin fibroblasts were performed as previously described with minor modifications (Michele <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0046" ref-type="ref">2002</xref>; Willer <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0075" ref-type="ref">2012</xref>). Briefly, PVDF membranes were incubated with EngelbrethâHolmâSwarm laminin (SigmaâAldrich) or agrin (R&amp;D Systems), overnight at 4Â°C in lamininâbinding buffer. Then, membranes were washed and incubated with antiâagrin (Millipore) or antiâlaminin (SigmaâAldrich) primary antibodies and their corresponding secondary antibodies. Blots were imaged using the protocol described for Western blots.</p>
      </sec>
      <sec id="emmm201505815-sec-0019">
        <title>Flow cytometry</title>
        <p>The following method was modified from Stevens <italic>etÂ al</italic> (<xref rid="emmm201505815-bib-0064" ref-type="ref">2013b</xref>). Briefly, an antiâÎ±âdystroglycan antibody IIH6 was used to assess the amount of Î±âdystroglycan glycosylation in fibroblasts from patients (II.4 and II.5) and two controls. Fibroblasts (passages 2â3) were grown until approximately 90% confluent. Cells were detached using Accutase (Sigma, UK), centrifuged for 3Â min at 500Â <italic>g</italic>, and counted and resuspended in PBS to a final density of 200,000 fibroblasts per milliliter, centrifuged at 3,000Â <italic>g</italic> for 3Â min, and incubated on ice with IIH6 for 30Â min, antiâmouse biotinylated IgM (Vector Labs, USA) for 20Â min, and streptavidinâPE (BD Pharmingen, UK) for 15Â min. After washing, cells were resuspended in 500Â ml of PBS and transferred to FACS tubes (Corning Science, Mex). Data were acquired using the BD FACS Canto II analyzer and analyzed using the BD FACSDiva software (BD Bioscience, US). Two separate controls for each fibroblast population were used: one without any staining to remove background and another without the primary antibody to gate the IIH6âpositive population. A total of 50,000 cells were analyzed per experiment. We assessed the percentage of IIH6âpositive cells as well as the level of IIH6 the mean fluorescence intensity (MFI).</p>
      </sec>
      <sec id="emmm201505815-sec-0020">
        <title>Genetic mapping</title>
        <p>Genomewide genotyping using the Illumina Infinium HumanOmni1âQuad, v1.0 BeadChip (Illumina, San Diego, CA, USA) was performed in the DNA samples of the four affected siblings (II.1, II.2, II.4, and II.5) and the unaffected sister (II.3), thus allowing the analysis of over one million assays for each sample. The chips were scanned, and data were loaded into Illumina Genome Studio V2009.1 software. Genome Viewer tool was used to visualize genomic copy number variation as well as individual genotypes. Log R ratio and B allele frequency, plotted along the entire genome for all SNPs on the array, were used to analyze all variants. CNV partition 2.4.4 was employed to automatically detect copy number variants as well as regions of extended homozygosity &gt;Â 500Â kb across the genome. Genotype success rates &gt;Â 99.7% were obtained for all assays (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S6</xref>).</p>
      </sec>
      <sec id="emmm201505815-sec-0021">
        <title>Exome sequencing</title>
        <p>The capture and subsequent sequencing of exonic regions of DNAÂ samples II.3, II.4, and II.5 was performed at Otogenetics Co (Norcross, GA, USA) using the solutionâbased SeqCap EZ Human Exome Library v2.0 (Roche NimbleGen, Madison, WI, USA) and theÂ Illumina HiSeq2000, with 100 pairedâend runs. An average coverage of 30Ã across the exome was achieved for all samples. Reads were aligned to the reference genome hg19 with DNAnexus software (Palo Alto, CA, USA) using default parameters. Single nucleotide polymorphisms and indels were identified and realigned using the Genome Analysis Toolkit (GATK). In order to discard common variants, genetic variations were further verified in the Database of Single Nucleotide Polymorphisms (dbSNP Build ID: 137; <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/">http://www.ncbi.nlm.nih.gov/SNP/</ext-link>), the exome variant serverÂ (EVS) of the National Heart, Lung, and Blood Institute GOÂ Exome Sequencing Project (Seattle, WA, USA; <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>), and the 1000 Genomes Project (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org/">http://www.1000genomes.org/</ext-link>).</p>
      </sec>
      <sec id="emmm201505815-sec-0022">
        <title>Segregation analysis</title>
        <p>Segregation analysis was performed by means of Sanger sequencing using the primers presented in <xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S4</xref>. Cycle sequencing was performed using the Dye Terminator Sequencing Kit (Applied Biosystems, Foster City, CA) and run on an ABI 3100 genetic analyzer. Sequence chromatograms were analyzed using the Sequencher software (Genecodes, Ann Arbor, MI).</p>
      </sec>
      <sec id="emmm201505815-sec-0023">
        <title>Genotyping</title>
        <p>Genotyping of the p.D233E mutation in <italic>POGLUT1</italic> gene in the Spanish and the Human Genome Diversity Project series was carried out by realâtime PCR using a custom TaqMan<sup>Â®</sup> Genomic Assay (Applied Biosystems, Foster City, CA) with appropriate primers and probes (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S5</xref>). Thermal cycling and endâpoint polymerase chain reaction (PCR) analysis was performed on a realâtime PCR instrument (ABI 7900HT, Applied Biosystems, Foster City, CA). DNA from family members II.3 and II.4 was used as positive controls in all experiments.</p>
      </sec>
      <sec id="emmm201505815-sec-0024">
        <title>
<italic>POGLUT1</italic> subcloning and mutagenesis</title>
        <p>Human <italic>POGLUT1</italic> cDNA cloned into the pEZâM02 vector was obtained from GeneCopoeia (Rockville, MD, USA). The p.D233E mutation was introduced with the QuikChange II siteâdirected mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA), as per manufacturer's indications, and confirmed by direct sequencing. The oligonucleotide sequences used for siteâdirected mutagenesis and Sanger sequencing were as follows: POGLUT1 5â²âCAGCCTCCGGACTCTAGCâ3â² and 5â²âTAATACGACTCACTATAGGGâ3â² for wildâtype and POGLUT1 5â²âTCTCGGAAAAACCCAAAACTTGTTGA<underline underline-style="single">G</underline>GCAGAATACACCAAAâ3â² and 5â²âTTTGGTGTATTCTGC<underline underline-style="single">C</underline>TCAACAAGTTTTGGGTTTTTCCGAGAâ3â² (mismatched nucleotide to the reference sequence is underlined) for the D233E mutant. cDNAs encoding the luminal domains of wild type and D233E mutant of human POGLUT1, starting from Arg24, were amplified by PCR using the primers, 5â²âATATATAAGCTTCACGCCAGAAGGAGTCAGGTTâ3â² and 5â²âATCTAGCTCGAGCTAGTTCAGTTTTCAACATTTTGGGâ3â², and subcloned into a pSecTag2c vector (Invitrogen) in frame with a Câterminal Myc/6xHis tag for expression in mammalian cells. The expression constructs for wildâtype human POGLUT1 in pcDNA4 or pTracer vector were also used as a template for siteâdirected mutagenesis to introduce the D233E mutation (Rana <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0055" ref-type="ref">2011</xref>; Takeuchi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0068" ref-type="ref">2012</xref>). The sequences of the primers are 5â²âCTTGTTGAGGCAGAATACACCAAAAACCAGGCCTGâ3â² and 5â²âGTATTCTGCCTCAACAAGTTTGGGTTTTTCCGAGACAGâ3â². The pcDNA4âbased construct encodes the recombinant protein with a Câterminal Myc/6xHis tag. The pTracerâbased construct encodes the recombinant protein with a FLAG tag, which is immediately downstream of the KTEL sequence at the Câterminus. Successful incorporation of the mutation was confirmed by direct DNA sequencing.</p>
      </sec>
      <sec id="emmm201505815-sec-0025">
        <title>
<italic>In vitro</italic> glycosylation assays</title>
        <p>Myc/6xHisâtagged POGLUT1 proteins were expressed in HEK293T cells by transient transfection, and the secreted proteins were purified from the culture media using NiâNTA agarose (QIAGEN). POGLUT/POXYLT assays were performed as previously described (FernandezâValdivia <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0022" ref-type="ref">2011</xref>). Briefly, a 10Â Î¼l standard reaction mixture contained 50Â mM HEPES pH 6.8, 10Â mM MnCl<sub>2</sub>, the indicated amounts of acceptor substrates, 0.16Â Î¼M UDPâ[6â<sup>3</sup>H]glucose (2.22 TBq/mmol), 10Â Î¼M UDPâglucose, 0.5% Nonidet Pâ40, and purified proteins. For POXYLT assay, 10Â Î¼M UDPâ[<sup>14</sup>C(U)]xylose (5.43Â GBq/mmol) was used as donor substrate. The reaction was performed at 37Â°C for 20Â min and stopped by adding 900Â Î¼l of 100Â mM EDTA pH 8.0. The sample was loaded onto a C18 cartridge (100Â mg, Agilent Technologies). After the cartridge was washed with 5Â ml of H<sub>2</sub>O, the EGF repeat was eluted with 1Â ml of 80% methanol. Incorporation of [6â<sup>3</sup>H]glucose or [<sup>14</sup>C(U)]xylose into the EGF repeats was determined by scintillation counting of the eluate. Reactions without substrates were used as background control. Data are from three independent assays. The values indicate meanÂ Â± SEM.</p>
        <p>
<italic>O</italic>âglucosylation or <italic>O</italic>âxylosylation of human factor IX EGF repeat and EGF16 from mouse Notch2 was performed using a modified POGLUT/POXYLT assay. A 100Â Î¼l reaction mixture contained 50Â mM HEPES pH 6.8, 10Â mM MnCl<sub>2</sub>, 10Â Î¼M acceptor substrate, 200Â Î¼M UDPâglucose, and purified wildâtype or D233E mutant POGLUT1. For <italic>O</italic>âxylosylation, 200Â Î¼M UDPâxylose was used as donor substrate. Approximately 500Â ng of each recombinant enzyme was used. The reaction was performed at 37Â°C overnight. The reaction products were purified by reverseâphase highâperformance liquid chromatography (RPâHPLC, Agilent Technologies, 1200 Series) equipped with a C18 column (10Â ÃÂ 250Â mm, VYDAC) with a linear gradient of solvent B (80% acetonitrile, 0.1% trifluoroacetic acid (TFA) in water) from 10 to 90% in solvent A (0.1% TFA in water) for 60Â min, monitoring absorbance at 214Â nm. Elution profiles between 20 and 30Â min are shown as milliâabsorbance unit (mAU). Peak fractions were pooled, dried down in a SpeedâVac centrifuge, and stored at â20Â°C for further mass spectral analysis.</p>
      </sec>
      <sec id="emmm201505815-sec-0026">
        <title>Mass spectrometric analysis of glycosylation products</title>
        <p>Mass spectrometric analysis by infusion was performed as described previously (Takeuchi <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0068" ref-type="ref">2012</xref>). Briefly, dried samples were resuspended in 0.1% formic acid in water, spinâfiltered, and injected into an Agilent 6340 ionâtrap mass spectrometer with a nanoâHPLC CHIPâCube interface at a rate of 18Â Î¼l/h. The MS peaks for MS/MS were chosen manually, and the data were analyzed using Agilent ChemStation data analysis software. The masses of EGF repeats with different charge states were deconvoluted and shown on the top of peaks in HPLC profiles.</p>
      </sec>
      <sec id="emmm201505815-sec-0027">
        <title>RTâPCR and qRTâPCR analysis</title>
        <p>Total RNA was extracted using QIAzol and RNeasy kit (Qiagen). cDNA was synthesized from 1Â Î¼g of total RNA using Transcriptor First Strand cDNA Synthesis Kit (Roche). qRTâPCR (100Â ng total cDNA per reaction) was performed using TaqMan<sup>Â®</sup> Fast Advanced Master Mix (Applied Biosystems) in a 7500 Fast RealâTime PCR System. Relative mRNA levels were compared using the <mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="nlm-math-1"><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:mo>â</mml:mo><mml:mi mathvariant="normal">Î</mml:mi><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:msub></mml:mrow></mml:msup></mml:math> method, with <italic>GAPDH</italic> as control (only POGLUT1 mRNA level was relative to desmin). We used TaqMan probes (Applied Biosystems) for human <italic>HES1</italic> (Hs00172878_m1), human <italic>PAX7</italic> (Hs00242962_m1), human <italic>POGLUT1</italic> (Hs00220308_m1), human <italic>GAPDH</italic> (Hs02758991_g1), human <italic>DES</italic> (Hs00157258_m1), mouse <italic>HES1</italic> (Mm01342805_m1), mouse <italic>Pax7</italic> (Mm01354484_m1), and mouse <italic>GAPDH</italic> (Mm03302249_g1).</p>
        <p>We selected the disease control muscles from patients with wellâcharacterized limbâgirdle muscular dystrophies. To avoid possible differences due to the effect of age on the satellite cell population (Chakkalakal <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0010" ref-type="ref">2012</xref>; SousaâVictor <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0061" ref-type="ref">2014</xref>), our samples of D233E patients and both healthy and disease controls were ageâmatched (<xref rid="emmm201505815-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S6</xref>).</p>
      </sec>
      <sec id="emmm201505815-sec-0028">
        <title>Generation of the transgenic fly</title>
        <p>To generate transgenic flies capable of overexpressing human POGLUT1<sup>D233E</sup>, a BamHIâXbaI fragment containing the POGLUT1<sup>D233E</sup> ORF was released from pTracerâPOGLUT1<sup>D233E</sup>âFLAG and cloned into the BglIIâXbaI sites of <italic>pUASTattB</italic> (Bischof <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0005" ref-type="ref">2007</xref>) to generate pUASTattBâPOGLUT1<sup>D233E</sup>âFLAG. Generation of pUASTattBâPOGLUT1<sup>wt</sup>âFLAG was described previously (FernandezâValdivia <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0022" ref-type="ref">2011</xref>). Both constructs were integrated into the <italic>VK22</italic> docking site by using Î¦C31âmediated transgenesis toÂ generate <italic>UASattBâPOGLUT1</italic>
<sup><italic>D233E</italic></sup>
<italic>âFLAG.VK22</italic> and <italic>UASattBâ POGLUT1</italic>
<sup><italic>WT</italic></sup>
<italic>âFLAG.VK22</italic> transgenes. Correct integration events were verified by att PCRs, as described previously (Venken <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0072" ref-type="ref">2006</xref>).</p>
      </sec>
      <sec id="emmm201505815-sec-0029">
        <title>Analysis of muscle phenotype in <italic>Drosophila</italic>
</title>
        <p>We assessed the effect of POGLUT1 activity toward the development of indirect flight muscles in <italic>Drosophila</italic> (Gildor <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0024" ref-type="ref">2012</xref>). Rescue experiments were performed with fly transgenes expressing human <italic>POGLUT1</italic>
<sup><italic>wt</italic></sup> (wild type) and human <italic>POGLUT1</italic>
<sup><italic>D233E</italic></sup>. <italic>w</italic>
<sup><italic>1118</italic></sup> (wt), <italic>rumi</italic>
<sup><italic>79/79</italic></sup>, <italic>Mef2âGAL4/UASattBâPOGLUT1</italic>
<sup><italic>WT</italic></sup>
<italic>âFLAG; rumi</italic>
<sup><italic>79/79</italic></sup>, and <italic>Mef2âGAL4/UASattBâPOGLUT</italic>
<sup><italic>D233E</italic></sup>
<italic>âFLAG; rumi</italic>
<sup><italic>79/79</italic></sup> animals were raised at 18Â°C until puparium formation. Pupae 0â1Â h after puparium formation (APF) were incubated at indicated temperatures until 25% pupal development. Pupal indirect flight muscles were dissected and stained using standard methods. Antibodies are rabbit Î±âTwist 1:5,000 (Roth <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0058" ref-type="ref">1989</xref>), mouse 22C10 1:50 (DSHB), mouse Î±âFLAG M2 1:100 (Sigma), donkeyâÎ±ârabbitâCy3 1:500, donkeyâÎ±âmouseâCy5 1:500 (Jackson ImmunoResearch Laboratories). Confocal images were scanned using a Leica TCSâSP5 microscope and processed with Amira5.2.2. Myotube lengths were measured using a twoâdimensional measurement tool in Amira5.2.2. Mean myotube lengths and standard deviations were calculated for <italic>rumi</italic>
<sup><italic>79/79</italic></sup> pupae with no rescue and <italic>rumi</italic>
<sup><italic>79/79</italic></sup> pupae overexpressing <italic>POGLUT1</italic>
<sup><italic>WT</italic></sup> (<italic>n</italic>Â =Â 22) or <italic>POGLUT1</italic>
<sup><italic>D233E</italic></sup> (<italic>n</italic>Â =Â 54). Oneâway ANOVA with Tukey's multiple comparisons test was used to determine the <italic>P</italic>âvalues. Images were processed with Adobe Photoshop CS5; figures were assembled in Adobe Illustrator CS5.</p>
      </sec>
      <sec id="emmm201505815-sec-0030">
        <title>C2C12 cell line culture and Notch inhibition assay</title>
        <p>C2C12 cell line was cultured in monolayer. The culture media for the C2C12 myoblast stage contains Dulbecco's minimal essential medium (DMEM, Gibco, BRL, Bethesda, MD), supplemented with 5% glutamine, 10% fetal bovine serum, 1% penicillinâstreptomycinâfungizone, and 23Â mM HEPES. The cultures were examined regularly to avoid overgrowth. For the Notch inhibition assay, we treated C2C12 myoblasts at 80â90% confluence with DAPT (SigmaâAldrich, USA), a Î³âsecretase inhibitor, and a wellâestablished inhibitor of Notch, a Î³âsecretase substrate, as previously published (Kuang <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0036" ref-type="ref">2007</xref>). We also treated C2C12 myoblasts with LY3039478 (ApexBio Technology LLC), a more specific and potent Notch inhibitor. For this experiment, culture proliferation and differentiation medium were modified by adding 50Â Î¼M DAPT or 25Â Î¼M LY3039478, and 50â25Â Î¼M DMSO for controls, respectively.</p>
      </sec>
      <sec id="emmm201505815-sec-0031">
        <title>Primary cell culture</title>
        <p>Muscle biopsies from two patients (II.4 and II.5), three ageâmatched healthy controls and three ageâmatched disease controls were used for the experiments. Muscle biopsies were minced and cultured in a monolayer. Briefly, the culture medium for the myoblast stage contains 75% Dulbecco's minimal essential medium (Invitrogen) and 25% M199 medium (Invitrogen), supplemented with 10% fetal bovine serum (FBS), 10Â Î¼g/ml insulin, 2Â mM glutamine, 100 units/ml penicillin, 100Â Î¼g/ml streptomycin, 0.25Â Î¼g/ml fungizone, 10Â ng/ml epidermal growth factor, and 25Â ng/ml fibroblast growth factor. To obtain highly purified myoblasts, each 10<sup>7</sup> cells were mixed with 20Â Î¼l of CD56âcoated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and incubated at 6â12Â°C for 15Â min. Unbound microbeads were removed by washing cells in excess PBS buffer followed by centrifugation at 300Â ÃÂ <italic>g</italic> for 10Â min. The cell pellet was resuspended in PBS buffer to a concentration of 2Â ÃÂ 10<sup>8</sup> cells/ml before separation on a midiMACS cell separator (Miltenyi Biotec, Bergisch Gladbach, Germany). CD56âpositive cells were seeded at 13,000 cells/cm<sup>2</sup> using the culture medium for the myoblast stage containing 15% of FBS and without growth factors to avoid interference with the results. We examine proliferation at different days. When the myoblasts started to fuse, the medium was substituted with one containing 2% of FBS. We measured the fusion index 4Â days after medium change by calculating the mean percentage of nuclei in myotubes in respect to the total number of nuclei (myoblastsÂ +Â myotubes).</p>
        <p>Human skin biopsies were minced and cultured. Fibroblasts were grown in DMEM containing 15% fetal bovine serum and 1% penicillinâstreptomycinâfungizone at 37Â°C with 5% CO<sub>2</sub>.</p>
      </sec>
      <sec id="emmm201505815-sec-0032">
        <title>Myoblast immortalization</title>
        <p>Myoblasts from II.4 patient and healthy control were transduced with lentiviral vectors encoding hTERT and cdk4 containing puromycin and neomycin selection markers, respectively. Transduced cells were selected with puromycin (1Â Î¼g/ml) for 6Â days and neomycin (1Â mg/ml) for 10Â days. Infected cells were purified using an immunomagnetic cell sorting system (MACS; Miltenyi) according to the manufacturer's instructions with antiâCD56 microbeads. Cells were seeded at clonal density, and individual myogenic clones were isolated and characterized.</p>
      </sec>
      <sec id="emmm201505815-sec-0033">
        <title>Fibroblast myogenic conversion</title>
        <p>Fibroblasts from II.4 patient and healthy control were transduced with lentiviral vector encoding hTert. Transduced cells were selected with puromycin (1Â Î¼g/ml) for 6Â days. Immortalized fibroblasts were then transduced with a lentiviral vector encoding inducible MyoD. For MyoD induction, doxycycline (2Â Î¼g/ml) was added in the proliferation medium (this day was considered day 0).</p>
      </sec>
      <sec id="emmm201505815-sec-0034">
        <title>Lentivirus generation and infection</title>
        <p>We generated lentiviral vectors (LV), based on the calcium phosphate method as previously described (Yoshida <italic>etÂ al</italic>, <xref rid="emmm201505815-bib-0079" ref-type="ref">2013</xref>). Briefly, HEK293T cells were transfected using transfer plasmids, EF.hICN1.CMV.GFP (#17623, Addgene) or EF.CMV.GFP, together with psPAX2 packaging and pMD2.G envelope plasmid DNA at a ratio of 4:3:1, respectively. Then, 48Â h postâtransfection, medium was collected, filtered, and concentrated by centrifugation for 90Â min at 105,000Â ÃÂ <italic>g</italic> using a SW 32 Ti Beckman rotor. Supernatant was completely removed and pellet diluted in 100Â Î¼l PBS overnight at 4Â°C, titered by FACS, and stored at â80Â°C until use. Immortalized myoblasts from patients were infected with LVâNICDâGFP or LVâGFP, and immortalized myoblasts from control with LVâGFP. After 7Â days, GFPâpositive cells were purified by FACS.</p>
      </sec>
      <sec id="emmm201505815-sec-0035">
        <title>Study approval</title>
        <p>This study was approved by the Institutional Research Ethic Committee at Hospital Universitario Virgen del RocÃ­o in Sevilla (Spain). Written informed consent was received from participants, prior to inclusion in the study, for genetic studies, for muscle and skin biopsies, and for pictures appearing in the manuscript.</p>
      </sec>
    </sec>
    <sec id="emmm201505815-sec-0037">
      <title>Author contributions</title>
      <p>CP and JC designed the study. ESâM performed Î±âdystroglycan expression and function studies, cell culture, satellite cells, and myogenesis analysis. HT performed biochemical <italic>inÂ vitro</italic> assays. TVL and BE performed the fly studies. CP, MCâS, YM, and CM handled patients and collected biological samples from the patients. ER and ESâM processed and studied muscle biopsy. CP, MCâS, and JAMâL analyzed the radiological findings. FM, CP, JLNâG, and LGâS analyzed protein expression and mRNA levels. JC and GP performed and genetic studies. MCR and XSâC performed cell culture. AB generated the immortalized cells. EAâG, EG, and RFâC provided critical discussion on the research. CP, MH, RSH, and HJâN supervised and mentored all work. CP coordinated all the study and wrote the initial manuscript. All authors contributed to the final version of the manuscript.</p>
    </sec>
    <sec id="emmm201505815-sec-0038">
      <title>Conflict of interest</title>
      <p>The authors declare that they have no conflict of interest.</p>
    </sec>
    <sec id="emmm201505815-sec-0039">
      <boxed-text position="float" content-type="box" id="emmm201505815-blk-0001" orientation="portrait">
        <caption>
          <title>The paper explained</title>
        </caption>
        <sec id="emmm201505815-sec-0040">
          <title>Problem</title>
          <p>The fact that in a significant number of patients suffering from a muscular dystrophy, the responsible gene is still unknown stimulates research to describe new molecular and cellular pathomechanisms underlying muscle degeneration. It is known that even in healthy individuals, common daily activities cause skeletal muscle lesions that are physiologically repaired through activation of satellite cells. Accordingly, it is logical to envision a scenario where alteration in the satellite cell homeostasis could lead to muscle fiber degeneration because of accumulation of unrepaired damage. Indeed, this appears to be the case with the family we present carrying a homozygous missense D233E mutation in <italic>POGLUT1</italic> gene: a muscular dystrophy as a consequence of defective muscle regeneration.</p>
        </sec>
        <sec id="emmm201505815-sec-0041">
          <title>Results</title>
          <p>It is widely known that Notch signaling pathway plays critical roles in the highly coordinated muscle regenerative process, maintaining an appropriate population of satellite cells and preventing premature differentiation. Our previous work in <italic>Drosophila</italic> and mammalian cell lines has shown that the addition of <italic>O</italic>âlinked glucose to Notch receptors by protein <italic>O</italic>âglucosyltransferase 1 (POGLUT1; also known as Rumi) is required for Notch signaling. In the investigated family, a homozygous missense D233E mutation in <italic>POGLUT1</italic> dramatically reduces its enzymatic activity on Notch. As a result, the investigated family shows a defect in Notch signaling with a significant depletion of satellite cells, resulting in defective muscle regeneration and ultimately leading to muscle dystrophy. In addition, primary myoblasts from our patients displayed reduced selfârenewal capacity and enhanced differentiation in culture, as expected under a Notch signaling defective environment. We show that the enzymatic activity of POGLUT1 is also essential for the formation of adult muscles by myoblasts in <italic>Drosophila</italic>. Moreover, crossâspecies overexpression studies in <italic>Drosophila</italic> indicate that the D233E mutation impairs the ability of human POGLUT1 in rescuing the muscle defects in flies lacking endogenous POGLUT1 activity. We have previously shown that complete loss of POGLUT1 results in embryonic lethality, but our patients only exhibit an adultâonset muscular dystrophy. Our data provide a clear explanation for this apparent discrepancy: First, the D233E does not affect the expression level and the subcellular localization of POGLUT1, and second, despite the severe decrease in the enzymatic activity of POGLUT1<sup>D233E</sup>, this mutant protein maintains a residual activity. Of note, our patients also exhibited a muscleâspecific reduction in glycosylation and laminin binding of Î±âdystroglycan. While these defects probably contribute to muscle dystrophy in our patients, we do not favor the hypothesis that they constitute the primary underlying mechanism for the disease, as Î±âdystroglycan lacks POGLUT1 target sites and patient fibroblasts show normal Î±âdystroglycan glycosylation and laminin binding. Instead, we propose that altered proliferation and differentiation of satellite cells due to decreased Notch signaling ultimately alter the Î±âdystroglycan glycosylation, which is a dynamic process during muscle differentiation.</p>
        </sec>
        <sec id="emmm201505815-sec-0042">
          <title>Impact</title>
          <p>Our data link a missense mutation in <italic>POGLUT1</italic> to a novel form of muscular dystrophy and suggest that Notchâdependent loss of satellite cells is the primary pathomechanism for the disease in ourÂ patients. The muscleâspecific phenotypes in our patients indicate that muscle stem cells are much more sensitive to a decrease in POGLUT1 enzymatic activity compared with other human cell types and suggest that small molecules affecting the activity of POGLUT1 in muscle could be of potential benefit in controlling the behavior of satellite cells, paving the way for potential future therapies.</p>
        </sec>
      </boxed-text>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data" id="emmm201505815-sup-0001">
        <caption>
          <p>Appendix</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505815-sup-0002">
        <caption>
          <p>Source Data for Appendix</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s002.zip">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>Review Process File</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s009.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505815-supp-data-0001">
        <caption>
          <p>Source Data for FigureÂ 2</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s003.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505815-supp-data-0002">
        <caption>
          <p>Source Data for FigureÂ 5</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s004.zip">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505815-supp-data-0003">
        <caption>
          <p>Source Data for FigureÂ 6</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s005.xlsx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505815-supp-data-0004">
        <caption>
          <p>Source Data for FigureÂ 7</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s006.xlsx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505815-supp-data-0005">
        <caption>
          <p>Source Data for FigureÂ 8</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s007.xlsx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505815-supp-data-0006">
        <caption>
          <p>Source Data for FigureÂ 9</p>
        </caption>
        <media xlink:href="EMMM-8-1289-s008.zip">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="emmm201505815-sec-0036">
      <title>Acknowledgements</title>
      <p>We thank Isabel Illa (Hospital Santa Creu i Sant Pau) and Salvatore DiMauro (Columbia University) for their critical comments; Montserrat OlivÃ©Â (Hospital de Bellvitge) for her supporting on muscle imaging; Cristina Dominguez (Hospital 12 Octubre) for ceding us muscle samples; and Gloria Cantero for helping with quantifications. Stephan KrÃ¶ger (MÃ¼nich University) for kind donation of the antibody against the Î±âdystroglycan core (clone no. 317); Maria Leptin (Cologne University) for antiâTwist antibody; David Comas (Institut de BiologÃ­a Evolutiva, Pompeu Fabra University), for providing DNA samples; Developmental Studies Hybridoma Bank for 22C10 antibody; Bloomington <italic>Drosophila</italic> stock center (NIH P40OD018537) for theÂ <italic>Mef2âGAL4</italic> strain; Confocal Microscopy Core of the BCM IDDRC (1U54HD083092; the Eunice Kennedy NICHD); Platform for immortalization of human cells of the Myology Institute in Paris; and Raquel GÃ³mez (Biomedicine Institute of Seville Pathology Core Facility), Juan J. PÃ©rezâMoreno (Centro Andaluz de BiologÃ­a del Desarrollo), and O. Akman (Columbia University) for their technical support. Supported in part by grants from the Health Institute Carlos III and FEDER (FIS PI10/02410, PI13â01739, and BA12â00097 to C. Paradas, FIS12/2291 to E. Gallardo, and CIBERNED to R. FernÃ¡ndezâChacÃ³n), the Andalusian Government (PIâ0017â2014 to C. Paradas and P12âCTSâ2232 to R. FernÃ¡ndezâChacÃ³n), The Matsumae International Foundation (to C. Paradas), the NIH/NIGMS (R01GM061126 to R.S. Haltiwanger and R01GM084135 to H. JafarâNejad), the NIH (U54 NS078059 from NINDS and NICHD, R01 HD056103 from NICHD to M. Hirano), and the MDA USA (to M. Hirano).</p>
    </ack>
    <ref-list content-type="cited-references" id="emmm201505815-bibl-0001">
      <title>References</title>
      <ref id="emmm201505815-bib-0001">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0001">
<string-name>
<surname>Acar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>JafarâNejad</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rajan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ibrani</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rana</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Bellen</surname>
<given-names>HJ</given-names>
</string-name> (<year>2008</year>) <article-title>Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is required for Notch signaling</article-title>. <source>Cell</source>
<volume>132</volume>: <fpage>247</fpage>â<lpage>258</lpage>
<pub-id pub-id-type="pmid">18243100</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0002">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0002">
<string-name>
<surname>Awano</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Blaeser</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>KeramarisâVrantsis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Q</given-names>
</string-name> (<year>2015</year>) <article-title>Dystroglycanopathy muscles lacking functional glycosylation of alphaâdystroglycan retain regeneration capacity</article-title>. <source>Neuromuscul Disord</source>
<volume>25</volume>: <fpage>474</fpage>â<lpage>484</lpage>
<pub-id pub-id-type="pmid">25937147</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0003">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0003">
<string-name>
<surname>Barresi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>2006</year>) <article-title>Dystroglycan: from biosynthesis to pathogenesis of human disease</article-title>. <source>J Cell Sci</source>
<volume>119</volume>: <fpage>199</fpage>â<lpage>207</lpage>
<pub-id pub-id-type="pmid">16410545</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0004">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0004">
<string-name>
<surname>Basmanav</surname>
<given-names>FB</given-names>
</string-name>, <string-name>
<surname>Oprisoreanu</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Pasternack</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Thiele</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Fritz</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wenzel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Grosser</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wehner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wolf</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fagerberg</surname>
<given-names>C</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2014</year>) <article-title>Mutations in POGLUT1, encoding protein Oâglucosyltransferase 1, cause autosomalâdominant dowlingâdegos disease</article-title>. <source>Am J Hum Genet</source>
<volume>94</volume>: <fpage>135</fpage>â<lpage>143</lpage>
<pub-id pub-id-type="pmid">24387993</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0005">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0005">
<string-name>
<surname>Bischof</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Hediger</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Karch</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Basler</surname>
<given-names>K</given-names>
</string-name> (<year>2007</year>) <article-title>An optimized transgenesis system for <italic>Drosophila</italic> using germâlineâspecific phiC31 integrases</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>104</volume>: <fpage>3312</fpage>â<lpage>3317</lpage>
<pub-id pub-id-type="pmid">17360644</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0006">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0006">
<string-name>
<surname>Bjornson</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Cheung</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tripathi</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Steeper</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Rando</surname>
<given-names>TA</given-names>
</string-name> (<year>2012</year>) <article-title>Notch signaling is necessary to maintain quiescence in adult muscle stem cells</article-title>. <source>Stem Cells</source>
<volume>30</volume>: <fpage>232</fpage>â<lpage>242</lpage>
<pub-id pub-id-type="pmid">22045613</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0007">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0007">
<string-name>
<surname>Bonnemann</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>QuijanoâRoy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Deconinck</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bertini</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ferreiro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Sewry</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Beroud</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mathews</surname>
<given-names>KD</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2014</year>) <article-title>Diagnostic approach to the congenital muscular dystrophies</article-title>. <source>Neuromuscul Disord</source>
<volume>24</volume>: <fpage>289</fpage>â<lpage>311</lpage>
<pub-id pub-id-type="pmid">24581957</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0008">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0008">
<string-name>
<surname>Brohl</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vasyutina</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Czajkowski</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Griger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rassek</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rahn</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Purfurst</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wende</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Birchmeier</surname>
<given-names>C</given-names>
</string-name> (<year>2012</year>) <article-title>Colonization of the satellite cell niche by skeletal muscle progenitor cells depends on Notch signals</article-title>. <source>Dev Cell</source>
<volume>23</volume>: <fpage>469</fpage>â<lpage>481</lpage>
<pub-id pub-id-type="pmid">22940113</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0009">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0009">
<string-name>
<surname>Carss</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Foley</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Cirak</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Riemersma</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Torelli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hoischen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Willer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>van Scherpenzeel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>SA</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2013</year>) <article-title>Mutations in GDPâmannose pyrophosphorylase B cause congenital and limbâgirdle muscular dystrophies associated with hypoglycosylation of alphaâdystroglycan</article-title>. <source>Am J Hum Genet</source>
<volume>93</volume>: <fpage>29</fpage>â<lpage>41</lpage>
<pub-id pub-id-type="pmid">23768512</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0010">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0010">
<string-name>
<surname>Chakkalakal</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Basson</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Brack</surname>
<given-names>AS</given-names>
</string-name> (<year>2012</year>) <article-title>The aged niche disrupts muscle stem cell quiescence</article-title>. <source>Nature</source>
<volume>490</volume>: <fpage>355</fpage>â<lpage>360</lpage>
<pub-id pub-id-type="pmid">23023126</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0011">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0011">
<string-name>
<surname>Chandrasekharan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>PT</given-names>
</string-name> (<year>2010</year>) <article-title>Genetic defects in muscular dystrophy</article-title>. <source>Methods Enzymol</source>
<volume>479</volume>: <fpage>291</fpage>â<lpage>322</lpage>
<pub-id pub-id-type="pmid">20816173</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0012">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0012">
<string-name>
<surname>Choi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Costa</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Mermelstein</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Chagas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Holtzer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Holtzer</surname>
<given-names>H</given-names>
</string-name> (<year>1990</year>) <article-title>MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>87</volume>: <fpage>7988</fpage>â<lpage>7992</lpage>
<pub-id pub-id-type="pmid">2172969</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0013">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0013">
<string-name>
<surname>Christian</surname>
<given-names>JL</given-names>
</string-name> (<year>2000</year>) <article-title>BMP, Wnt and Hedgehog signals: how far can they go?</article-title>
<source>Curr Opin Cell Biol</source>
<volume>12</volume>: <fpage>244</fpage>â<lpage>249</lpage>
<pub-id pub-id-type="pmid">10819541</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0014">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0014">
<string-name>
<surname>Cirak</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Foley</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Herrmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Willer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yau</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Torelli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brodd</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kamynina</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vondracek</surname>
<given-names>P</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2013</year>) <article-title>ISPD gene mutations are a common cause of congenital and limbâgirdle muscular dystrophies</article-title>. <source>Brain</source>
<volume>136</volume>: <fpage>269</fpage>â<lpage>281</lpage>
<pub-id pub-id-type="pmid">23288328</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0015">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0015">
<string-name>
<surname>Cohn</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Michele</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Barresi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Flanagan</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Skwarchuk</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Robbins</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Mendell</surname>
<given-names>JR</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2002</year>) <article-title>Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration</article-title>. <source>Cell</source>
<volume>110</volume>: <fpage>639</fpage>â<lpage>648</lpage>
<pub-id pub-id-type="pmid">12230980</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0016">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0016">
<string-name>
<surname>Collins</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Zammit</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Heslop</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Petrie</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Partridge</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>
<given-names>JE</given-names>
</string-name> (<year>2005</year>) <article-title>Stem cell function, selfârenewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche</article-title>. <source>Cell</source>
<volume>122</volume>: <fpage>289</fpage>â<lpage>301</lpage>
<pub-id pub-id-type="pmid">16051152</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0017">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0017">
<string-name>
<surname>Conboy</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Rando</surname>
<given-names>TA</given-names>
</string-name> (<year>2002</year>) <article-title>The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis</article-title>. <source>Dev Cell</source>
<volume>3</volume>: <fpage>397</fpage>â<lpage>409</lpage>
<pub-id pub-id-type="pmid">12361602</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0018">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0018">
<string-name>
<surname>Cote</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Moukhles</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lindenbaum</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Carbonetto</surname>
<given-names>S</given-names>
</string-name> (<year>1999</year>) <article-title>Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses</article-title>. <source>Nat Genet</source>
<volume>23</volume>: <fpage>338</fpage>â<lpage>342</lpage>
<pub-id pub-id-type="pmid">10610181</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0019">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0019">
<string-name>
<surname>Ervasti</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Ohlendieck</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kahl</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Gaver</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>1990</year>) <article-title>Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle</article-title>. <source>Nature</source>
<volume>345</volume>: <fpage>315</fpage>â<lpage>319</lpage>
<pub-id pub-id-type="pmid">2188135</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0020">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0020">
<string-name>
<surname>Ervasti</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>1991</year>) <article-title>Membrane organization of the dystrophinâglycoprotein complex</article-title>. <source>Cell</source>
<volume>66</volume>: <fpage>1121</fpage>â<lpage>1131</lpage>
<pub-id pub-id-type="pmid">1913804</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0021">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0021">
<string-name>
<surname>Ervasti</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>1993</year>) <article-title>A role for the dystrophinâglycoprotein complex as a transmembrane linker between laminin and actin</article-title>. <source>J Cell Biol</source>
<volume>122</volume>: <fpage>809</fpage>â<lpage>823</lpage>
<pub-id pub-id-type="pmid">8349731</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0022">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0022">
<string-name>
<surname>FernandezâValdivia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Samarghandi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>JafarâNejad</surname>
<given-names>H</given-names>
</string-name> (<year>2011</year>) <article-title>Regulation of mammalian Notch signaling and embryonic development by the protein Oâglucosyltransferase Rumi</article-title>. <source>Development</source>
<volume>138</volume>: <fpage>1925</fpage>â<lpage>1934</lpage>
<pub-id pub-id-type="pmid">21490058</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0023">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0023">
<string-name>
<surname>Freeze</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Chong</surname>
<given-names>JX</given-names>
</string-name>, <string-name>
<surname>Bamshad</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>BG</given-names>
</string-name> (<year>2014</year>) <article-title>Solving glycosylation disorders: fundamental approaches reveal complicated pathways</article-title>. <source>Am J Hum Genet</source>
<volume>94</volume>: <fpage>161</fpage>â<lpage>175</lpage>
<pub-id pub-id-type="pmid">24507773</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0024">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0024">
<string-name>
<surname>Gildor</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Schejter</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Shilo</surname>
<given-names>BZ</given-names>
</string-name> (<year>2012</year>) <article-title>Bidirectional Notch activation represses fusion competence in swarming adult <italic>Drosophila</italic> myoblasts</article-title>. <source>Development</source>
<volume>139</volume>: <fpage>4040</fpage>â<lpage>4050</lpage>
<pub-id pub-id-type="pmid">23048185</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0025">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0025">
<string-name>
<surname>Goddeeris</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Venzke</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>YoshidaâMoriguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Matsumura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>2013</year>) <article-title>LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy</article-title>. <source>Nature</source>
<volume>503</volume>: <fpage>136</fpage>â<lpage>140</lpage>
<pub-id pub-id-type="pmid">24132234</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0026">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0026">
<string-name>
<surname>Haltom</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>TV</given-names>
</string-name>, <string-name>
<surname>Harvey</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>JafarâNejad</surname>
<given-names>H</given-names>
</string-name> (<year>2014</year>) <article-title>The protein Oâglucosyltransferase Rumi modifies eyes shut to promote rhabdomere separation in <italic>Drosophila</italic>
</article-title>. <source>PLoS Genet</source>
<volume>10</volume>: <fpage>e1004795</fpage>
<pub-id pub-id-type="pmid">25412384</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0027">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0027">
<string-name>
<surname>Hara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>BalciâHayta</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>YoshidaâMoriguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kanagawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>BeltranâValero de Bernabe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gundesli</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Willer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Satz</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Crawford</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Burden</surname>
<given-names>SJ</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2011</year>) <article-title>A dystroglycan mutation associated with limbâgirdle muscular dystrophy</article-title>. <source>N Engl J Med</source>
<volume>364</volume>: <fpage>939</fpage>â<lpage>946</lpage>
<pub-id pub-id-type="pmid">21388311</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0028">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0028">
<string-name>
<surname>Hase</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kawabata</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takeya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sueyoshi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Miyata</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Iwanaga</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takao</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shimonishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ikenaka</surname>
<given-names>T</given-names>
</string-name> (<year>1988</year>) <article-title>A new trisaccharide sugar chain linked to a serine residue in bovine blood coagulation factors VII and IX</article-title>. <source>J Biochem</source>
<volume>104</volume>: <fpage>867</fpage>â<lpage>868</lpage>
<pub-id pub-id-type="pmid">3149637</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0029">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0029">
<string-name>
<surname>Henry</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>1998</year>) <article-title>A role for dystroglycan in basement membrane assembly</article-title>. <source>Cell</source>
<volume>95</volume>: <fpage>859</fpage>â<lpage>870</lpage>
<pub-id pub-id-type="pmid">9865703</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0030">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0030">
<string-name>
<surname>Herrmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Straub</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Blank</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kutzick</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Franke</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Jacob</surname>
<given-names>EN</given-names>
</string-name>, <string-name>
<surname>Lenard</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Kroger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Voit</surname>
<given-names>T</given-names>
</string-name> (<year>2000</year>) <article-title>Dissociation of the dystroglycan complex in caveolinâ3âdeficient limb girdle muscular dystrophy</article-title>. <source>Hum Mol Genet</source>
<volume>9</volume>: <fpage>2335</fpage>â<lpage>2340</lpage>
<pub-id pub-id-type="pmid">11001938</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0031">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0031">
<string-name>
<surname>Hori</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>ArtavanisâTsakonas</surname>
<given-names>S</given-names>
</string-name> (<year>2013</year>) <article-title>Notch signaling at a glance</article-title>. <source>J Cell Sci</source>
<volume>126</volume>: <fpage>2135</fpage>â<lpage>2140</lpage>
<pub-id pub-id-type="pmid">23729744</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0032">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0032">
<string-name>
<surname>Inamori</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>YoshidaâMoriguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>2012</year>) <article-title>Dystroglycan function requires xylosylâ and glucuronyltransferase activities of LARGE</article-title>. <source>Science</source>
<volume>335</volume>: <fpage>93</fpage>â<lpage>96</lpage>
<pub-id pub-id-type="pmid">22223806</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0033">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0033">
<string-name>
<surname>JafarâNejad</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>FernandezâValdivia</surname>
<given-names>R</given-names>
</string-name> (<year>2010</year>) <article-title>Role of glycans and glycosyltransferases in the regulation of Notch signaling</article-title>. <source>Glycobiology</source>
<volume>20</volume>: <fpage>931</fpage>â<lpage>949</lpage>
<pub-id pub-id-type="pmid">20368670</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0034">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0034">
<string-name>
<surname>Johnston</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Rauskolb</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Prabhakaran</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Irvine</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Vogt</surname>
<given-names>TF</given-names>
</string-name> (<year>1997</year>) <article-title>A family of mammalian Fringe genes implicated in boundary determination and the Notch pathway</article-title>. <source>Development</source>
<volume>124</volume>: <fpage>2245</fpage>â<lpage>2254</lpage>
<pub-id pub-id-type="pmid">9187150</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0035">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0035">
<string-name>
<surname>Kanagawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tajiri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Manya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kuga</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yamaguchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>AkasakaâManya</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Furukawa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kawakami</surname>
<given-names>H</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2016</year>) <article-title>Identification of a postâtranslational modification with ribitolâphosphate and its defect in muscular dystrophy</article-title>. <source>Cell Rep</source>
<volume>14</volume>: <fpage>2209</fpage>â<lpage>2223</lpage>
<pub-id pub-id-type="pmid">26923585</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0036">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0036">
<string-name>
<surname>Kuang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kuroda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Le Grand</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rudnicki</surname>
<given-names>MA</given-names>
</string-name> (<year>2007</year>) <article-title>Asymmetric selfârenewal and commitment of satellite stem cells in muscle</article-title>. <source>Cell</source>
<volume>129</volume>: <fpage>999</fpage>â<lpage>1010</lpage>
<pub-id pub-id-type="pmid">17540178</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0037">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0037">
<string-name>
<surname>Lee</surname>
<given-names>TV</given-names>
</string-name>, <string-name>
<surname>Sethi</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rana</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Buettner</surname>
<given-names>FF</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Bakker</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>JafarâNejad</surname>
<given-names>H</given-names>
</string-name> (<year>2013</year>) <article-title>Negative regulation of notch signaling by xylose</article-title>. <source>PLoS Genet</source>
<volume>9</volume>: <fpage>e1003547</fpage>
<pub-id pub-id-type="pmid">23754965</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0038">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0038">
<string-name>
<surname>Leonardi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>FernandezâValdivia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>YD</given-names>
</string-name>, <string-name>
<surname>Simcox</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>JafarâNejad</surname>
<given-names>H</given-names>
</string-name> (<year>2011</year>) <article-title>Multiple Oâglucosylation sites on Notch function as a buffer against temperatureâdependent loss of signaling</article-title>. <source>Development</source>
<volume>138</volume>: <fpage>3569</fpage>â<lpage>3578</lpage>
<pub-id pub-id-type="pmid">21771811</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0039">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0039">
<string-name>
<surname>Li</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jiao</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>J</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2013</year>) <article-title>Mutations in POFUT1, encoding protein Oâfucosyltransferase 1, cause generalized DowlingâDegos disease</article-title>. <source>Am J Hum Genet</source>
<volume>92</volume>: <fpage>895</fpage>â<lpage>903</lpage>
<pub-id pub-id-type="pmid">23684010</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0040">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0040">
<string-name>
<surname>Lin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Keller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pear</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>L</given-names>
</string-name> (<year>2013</year>) <article-title>Brief report: blockade of Notch signaling in muscle stem cells causes muscular dystrophic phenotype and impaired muscle regeneration</article-title>. <source>Stem Cells</source>
<volume>31</volume>: <fpage>823</fpage>â<lpage>828</lpage>
<pub-id pub-id-type="pmid">23307608</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0041">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0041">
<string-name>
<surname>Ma</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name> (<year>2011</year>) <article-title>hCLP46 regulates U937 cell proliferation via Notch signaling pathway</article-title>. <source>Biochem Biophys Res Commun</source>
<volume>408</volume>: <fpage>84</fpage>â<lpage>88</lpage>
<pub-id pub-id-type="pmid">21458412</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0042">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0042">
<string-name>
<surname>Malfatti</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Olive</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Taratuto</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Richard</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Brochier</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bitoun</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gueneau</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Laforet</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Stojkovic</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Maisonobe</surname>
<given-names>T</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2013</year>) <article-title>Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1ârelated disorders</article-title>. <source>J Neuropathol Exp Neurol</source>
<volume>72</volume>: <fpage>833</fpage>â<lpage>845</lpage>
<pub-id pub-id-type="pmid">23965743</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0043">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0043">
<string-name>
<surname>Mamchaoui</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Trollet</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bigot</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Negroni</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Chaouch</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wolff</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kandalla</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Marie</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Di Santo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>St Guily</surname>
<given-names>JL</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2011</year>) <article-title>Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders</article-title>. <source>Skelet Muscle</source>
<volume>1</volume>: <fpage>34</fpage>
<pub-id pub-id-type="pmid">22040608</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0044">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0044">
<string-name>
<surname>Manya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chiba</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chiba</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jigami</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Margolis</surname>
<given-names>RU</given-names>
</string-name>, <string-name>
<surname>Endo</surname>
<given-names>T</given-names>
</string-name> (<year>2004</year>) <article-title>Demonstration of mammalian protein Oâmannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>101</volume>: <fpage>500</fpage>â<lpage>505</lpage>
<pub-id pub-id-type="pmid">14699049</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0045">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0045">
<string-name>
<surname>Mauro</surname>
<given-names>A</given-names>
</string-name> (<year>1961</year>) <article-title>Satellite cell of skeletal muscle fibers</article-title>. <source>J Biophys Biochem Cytol</source>
<volume>9</volume>: <fpage>493</fpage>â<lpage>495</lpage>
<pub-id pub-id-type="pmid">13768451</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0046">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0046">
<string-name>
<surname>Michele</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Barresi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kanagawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cohn</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Satz</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Dollar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nishino</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kelley</surname>
<given-names>RI</given-names>
</string-name>, <string-name>
<surname>Somer</surname>
<given-names>H</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2002</year>) <article-title>Postâtranslational disruption of dystroglycanâligand interactions in congenital muscular dystrophies</article-title>. <source>Nature</source>
<volume>418</volume>: <fpage>417</fpage>â<lpage>422</lpage>
<pub-id pub-id-type="pmid">12140558</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0047">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0047">
<string-name>
<surname>Moloney</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Shair</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Locke</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Matta</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name> (<year>2000</year>) <article-title>Mammalian Notch1 is modified with two unusual forms of Oâlinked glycosylation found on epidermal growth factorâlike modules</article-title>. <source>J Biol Chem</source>
<volume>275</volume>: <fpage>9604</fpage>â<lpage>9611</lpage>
<pub-id pub-id-type="pmid">10734111</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0048">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0048">
<string-name>
<surname>Mourikis</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tajbakhsh</surname>
<given-names>S</given-names>
</string-name> (<year>2014</year>) <article-title>Distinct contextual roles for Notch signalling in skeletal muscle stem cells</article-title>. <source>BMC Dev Biol</source>
<volume>14</volume>: <fpage>2</fpage>
<pub-id pub-id-type="pmid">24472470</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0049">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0049">
<string-name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Torelli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wells</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>SC</given-names>
</string-name> (<year>2011</year>) <article-title>Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies</article-title>. <source>Curr Opin Neurol</source>
<volume>24</volume>: <fpage>437</fpage>â<lpage>442</lpage>
<pub-id pub-id-type="pmid">21825985</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0050">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0050">
<string-name>
<surname>Nakamura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lyalin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Panin</surname>
<given-names>VM</given-names>
</string-name> (<year>2010</year>) <article-title>Protein Oâmannosylation in animal development and physiology: from human disorders to <italic>Drosophila</italic> phenotypes</article-title>. <source>Semin Cell Dev Biol</source>
<volume>21</volume>: <fpage>622</fpage>â<lpage>630</lpage>
<pub-id pub-id-type="pmid">20362685</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0051">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0051">
<string-name>
<surname>Okajima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lei</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Irvine</surname>
<given-names>KD</given-names>
</string-name> (<year>2005</year>) <article-title>Chaperone activity of protein Oâfucosyltransferase 1 promotes notch receptor folding</article-title>. <source>Science</source>
<volume>307</volume>: <fpage>1599</fpage>â<lpage>1603</lpage>
<pub-id pub-id-type="pmid">15692013</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0052">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0052">
<string-name>
<surname>Olguin</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Olwin</surname>
<given-names>BB</given-names>
</string-name> (<year>2004</year>) <article-title>Paxâ7 upâregulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for selfârenewal</article-title>. <source>Dev Biol</source>
<volume>275</volume>: <fpage>375</fpage>â<lpage>388</lpage>
<pub-id pub-id-type="pmid">15501225</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0053">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0053">
<string-name>
<surname>Rahimov</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kunkel</surname>
<given-names>LM</given-names>
</string-name> (<year>2013</year>) <article-title>The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy</article-title>. <source>J Cell Biol</source>
<volume>201</volume>: <fpage>499</fpage>â<lpage>510</lpage>
<pub-id pub-id-type="pmid">23671309</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0054">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0054">
<string-name>
<surname>Ramkumar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Harvey</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Alcorn</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>SilvaâGagliardi</surname>
<given-names>NF</given-names>
</string-name>, <string-name>
<surname>McGlade</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Bestor</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Wijnholds</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>KV</given-names>
</string-name> (<year>2015</year>) <article-title>Protein Oâglucosyltransferase 1 (POGLUT1) promotes mouse gastrulation through modification of the apical polarity protein CRUMBS2</article-title>. <source>PLoS Genet</source>
<volume>11</volume>: <fpage>e1005551</fpage>
<pub-id pub-id-type="pmid">26496195</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0055">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0055">
<string-name>
<surname>Rana</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>NitaâLazar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kakuda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Luther</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name> (<year>2011</year>) <article-title>Oâglucose trisaccharide is present at high but variable stoichiometry at multiple sites on mouse Notch1</article-title>. <source>J Biol Chem</source>
<volume>286</volume>: <fpage>31623</fpage>â<lpage>31637</lpage>
<pub-id pub-id-type="pmid">21757702</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0056">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0056">
<string-name>
<surname>Riemersma</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Froese</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>van Tol</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Engelke</surname>
<given-names>UF</given-names>
</string-name>, <string-name>
<surname>Kopec</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>van Scherpenzeel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ashikov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Krojer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>von Delft</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Tessari</surname>
<given-names>M</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2015</year>) <article-title>Human ISPD is a cytidyltransferase required for dystroglycan Oâmannosylation</article-title>. <source>Chem Biol</source>
<volume>22</volume>: <fpage>1643</fpage>â<lpage>1652</lpage>
<pub-id pub-id-type="pmid">26687144</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0057">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0057">
<string-name>
<surname>Ross</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Benn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jonuschies</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Boldrin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hewitt</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>
<given-names>JE</given-names>
</string-name> (<year>2012</year>) <article-title>Defects in glycosylation impair satellite stem cell function and niche composition in the muscles of the dystrophic Large(myd) mouse</article-title>. <source>Stem Cells</source>
<volume>30</volume>: <fpage>2330</fpage>â<lpage>2341</lpage>
<pub-id pub-id-type="pmid">22887880</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0058">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0058">
<string-name>
<surname>Roth</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>NussleinâVolhard</surname>
<given-names>C</given-names>
</string-name> (<year>1989</year>) <article-title>A gradient of nuclear localization of the dorsal protein determines dorsoventral pattern in the <italic>Drosophila</italic> embryo</article-title>. <source>Cell</source>
<volume>59</volume>: <fpage>1189</fpage>â<lpage>1202</lpage>
<pub-id pub-id-type="pmid">2688897</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0059">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0059">
<string-name>
<surname>Sacco</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Doyonnas</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kraft</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vitorovic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Blau</surname>
<given-names>HM</given-names>
</string-name> (<year>2008</year>) <article-title>Selfârenewal and expansion of single transplanted muscle stem cells</article-title>. <source>Nature</source>
<volume>456</volume>: <fpage>502</fpage>â<lpage>506</lpage>
<pub-id pub-id-type="pmid">18806774</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0060">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0060">
<string-name>
<surname>Song</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bonaguidi</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Meletis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>ZJ</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Enikolopov</surname>
<given-names>G</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2012</year>) <article-title>Neuronal circuitry mechanism regulating adult quiescent neural stemâcell fate decision</article-title>. <source>Nature</source>
<volume>489</volume>: <fpage>150</fpage>â<lpage>154</lpage>
<pub-id pub-id-type="pmid">22842902</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0061">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0061">
<string-name>
<surname>SousaâVictor</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gutarra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>GarciaâPrat</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>RodriguezâUbreva</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ortet</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>RuizâBonilla</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Jardi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ballestar</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Serrano</surname>
<given-names>AL</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2014</year>) <article-title>Geriatric muscle stem cells switch reversible quiescence into senescence</article-title>. <source>Nature</source>
<volume>506</volume>: <fpage>316</fpage>â<lpage>321</lpage>
<pub-id pub-id-type="pmid">24522534</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0062">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0062">
<string-name>
<surname>Stanley</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Okajima</surname>
<given-names>T</given-names>
</string-name> (<year>2010</year>) <article-title>Roles of glycosylation in Notch signaling</article-title>. <source>Curr Top Dev Biol</source>
<volume>92</volume>: <fpage>131</fpage>â<lpage>164</lpage>
<pub-id pub-id-type="pmid">20816394</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0063">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0063">
<string-name>
<surname>Stevens</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Carss</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Cirak</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Foley</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Torelli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Willer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tambunan</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Yau</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brodd</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sewry</surname>
<given-names>CA</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2013a</year>) <article-title>Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of alphaâdystroglycan</article-title>. <source>Am J Hum Genet</source>
<volume>92</volume>: <fpage>354</fpage>â<lpage>365</lpage>
<pub-id pub-id-type="pmid">23453667</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0064">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0064">
<string-name>
<surname>Stevens</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Torelli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Phadke</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Walter</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Schneiderat</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Eddaoudi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sewry</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</string-name> (<year>2013b</year>) <article-title>Flow cytometry for the analysis of alphaâdystroglycan glycosylation in fibroblasts from patients with dystroglycanopathies</article-title>. <source>PLoS ONE</source>
<volume>8</volume>: <fpage>e68958</fpage>
<pub-id pub-id-type="pmid">23894383</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0065">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0065">
<string-name>
<surname>Sun</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zolkiewska</surname>
<given-names>A</given-names>
</string-name> (<year>2008</year>) <article-title>The role of Deltaâlike 1 shedding in muscle cell selfârenewal and differentiation</article-title>. <source>J Cell Sci</source>
<volume>121</volume>: <fpage>3815</fpage>â<lpage>3823</lpage>
<pub-id pub-id-type="pmid">18957511</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0066">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0066">
<string-name>
<surname>Takeuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name> (<year>2010</year>) <article-title>Role of glycosylation of Notch in development</article-title>. <source>Semin Cell Dev Biol</source>
<volume>21</volume>: <fpage>638</fpage>â<lpage>645</lpage>
<pub-id pub-id-type="pmid">20226260</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0067">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0067">
<string-name>
<surname>Takeuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>FernandezâValdivia</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Caswell</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>NitaâLazar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rana</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Garner</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Weldeghiorghis</surname>
<given-names>TK</given-names>
</string-name>, <string-name>
<surname>Macnaughtan</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>JafarâNejad</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name> (<year>2011</year>) <article-title>Rumi functions as both a protein Oâglucosyltransferase and a protein Oâxylosyltransferase</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>108</volume>: <fpage>16600</fpage>â<lpage>16605</lpage>
<pub-id pub-id-type="pmid">21949356</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0068">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0068">
<string-name>
<surname>Takeuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kantharia</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sethi</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Bakker</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name> (<year>2012</year>) <article-title>Siteâspecific Oâglucosylation of the epidermal growth factorâlike (EGF) repeats of notch: efficiency of glycosylation is affected by proper folding and amino acid sequence of individual EGF repeats</article-title>. <source>J Biol Chem</source>
<volume>287</volume>: <fpage>33934</fpage>â<lpage>33944</lpage>
<pub-id pub-id-type="pmid">22872643</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0069">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0069">
<string-name>
<surname>Takeuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name> (<year>2014</year>) <article-title>Significance of glycosylation in Notch signaling</article-title>. <source>Biochem Biophys Res Commun</source>
<volume>453</volume>: <fpage>235</fpage>â<lpage>242</lpage>
<pub-id pub-id-type="pmid">24909690</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0070">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0070">
<string-name>
<surname>Thakurdas</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Kakuda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>FernandezâValdivia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>ZarrinâKhameh</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Haltiwanger</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>JafarâNejad</surname>
<given-names>H</given-names>
</string-name> (<year>2016</year>) <article-title>Jagged1 heterozygosity in mice results in a congenital cholangiopathy which is reversed by concomitant deletion of one copy of Poglut1 (Rumi)</article-title>. <source>Hepatology</source>
<volume>63</volume>: <fpage>550</fpage>â<lpage>565</lpage>
<pub-id pub-id-type="pmid">26235536</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0071">
        <mixed-citation publication-type="book" id="emmm201505815-cit-0071">
<string-name>
<surname>Varki</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sharon</surname>
<given-names>N</given-names>
</string-name> (<year>2009</year>) <chapter-title>Historical background and overview</chapter-title> In <source>Essentials of glycobiology</source>, <person-group person-group-type="editor"><name><surname>Varki</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Cummings</surname><given-names>RD</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Esko</surname><given-names>JD</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Freeze</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Stanley</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Bertozzi</surname><given-names>CR</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Hart</surname><given-names>GW</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Etzler</surname><given-names>EE</given-names></name></person-group> (eds), pp <fpage>1</fpage>â<lpage>22</lpage>. <publisher-loc>New York</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
</mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0072">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0072">
<string-name>
<surname>Venken</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hoskins</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Bellen</surname>
<given-names>HJ</given-names>
</string-name> (<year>2006</year>) <article-title>P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in <italic>D.Â melanogaster</italic>
</article-title>. <source>Science</source>
<volume>314</volume>: <fpage>1747</fpage>â<lpage>1751</lpage>
<pub-id pub-id-type="pmid">17138868</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0073">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0073">
<string-name>
<surname>Vieira</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Elvers</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Moreira</surname>
<given-names>YB</given-names>
</string-name>, <string-name>
<surname>Eran</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gomes</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Marshall</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Karlsson</surname>
<given-names>EK</given-names>
</string-name>, <string-name>
<surname>VerjovskiâAlmeida</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>LindbladâToh</surname>
<given-names>K</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2015</year>) <article-title>Jagged 1 rescues the duchenne muscular dystrophy phenotype</article-title>. <source>Cell</source>
<volume>163</volume>: <fpage>1204</fpage>â<lpage>1213</lpage>
<pub-id pub-id-type="pmid">26582133</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0074">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0074">
<string-name>
<surname>Willer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Prados</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>FalconâPerez</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>RennerâMuller</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Przemeck</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Lommel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Coloma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Valero</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>de Angelis</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Tanner</surname>
<given-names>W</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2004</year>) <article-title>Targeted disruption of the WalkerâWarburg syndrome gene Pomt1 in mouse results in embryonic lethality</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>101</volume>: <fpage>14126</fpage>â<lpage>14131</lpage>
<pub-id pub-id-type="pmid">15383666</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0075">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0075">
<string-name>
<surname>Willer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lommel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>YoshidaâMoriguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>de Bernabe</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Venzke</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cirak</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schachter</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Vajsar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Voit</surname>
<given-names>T</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2012</year>) <article-title>ISPD lossâofâfunction mutations disrupt dystroglycan Oâmannosylation and cause WalkerâWarburg syndrome</article-title>. <source>Nat Genet</source>
<volume>44</volume>: <fpage>575</fpage>â<lpage>580</lpage>
<pub-id pub-id-type="pmid">22522420</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0076">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0076">
<string-name>
<surname>Willer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inamori</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Venzke</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Harvey</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Morgensen</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Beltran Valero de Bernabe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>2014</year>) <article-title>The glucuronyltransferase B4GAT1 is required for initiation of LARGEâmediated alphaâdystroglycan functional glycosylation</article-title>. <source>eLife</source>
<volume>3</volume>: <fpage>e03941</fpage>
</mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0077">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0077">
<string-name>
<surname>Yamamoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Toyoda</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Osawa</surname>
<given-names>M</given-names>
</string-name> (<year>1997</year>) <article-title>Pialâglial barrier abnormalities in fetuses with Fukuyama congenital muscular dystrophy</article-title>. <source>Brain Dev</source>
<volume>19</volume>: <fpage>35</fpage>â<lpage>42</lpage>
<pub-id pub-id-type="pmid">9071488</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0078">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0078">
<string-name>
<surname>Yan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>X</given-names>
</string-name> (<year>2009</year>) <article-title>Shaping morphogen gradients by proteoglycans</article-title>. <source>Cold Spring Harb Perspect Biol</source>
<volume>1</volume>: <fpage>a002493</fpage>
<pub-id pub-id-type="pmid">20066107</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0079">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0079">
<string-name>
<surname>Yoshida</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tsutsumi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Muhlebach</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sourbier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vartholomaiou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tatokoro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Beebe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miyajima</surname>
<given-names>N</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2013</year>) <article-title>Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>110</volume>: <fpage>E1604</fpage>â<lpage>E1612</lpage>
<pub-id pub-id-type="pmid">23564345</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505815-bib-0080">
        <mixed-citation publication-type="journal" id="emmm201505815-cit-0080">
<string-name>
<surname>YoshidaâMoriguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Willer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Venzke</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Whyte</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</string-name> (<year>2013</year>) <article-title>SGK196 is a glycosylationâspecific Oâmannose kinase required for dystroglycan function</article-title>. <source>Science</source>
<volume>341</volume>: <fpage>896</fpage>â<lpage>899</lpage>
<pub-id pub-id-type="pmid">23929950</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>